
==== Front
Int J Mol Sci
Int J Mol Sci
ijms
International Journal of Molecular Sciences
1422-0067
MDPI

10.3390/ijms25115601
ijms-25-05601
Review
The Basic Requirement of Tight Junction Proteins in Blood-Brain Barrier Function and Their Role in Pathologies
Dithmer Sophie 1
Blasig Ingolf E. 1
Fraser Paul A. 2
Qin Zhihai 3*†
Haseloff Reiner F. 1*
Cha Hee-Jae Academic Editor
1 Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Robert-Rössle-Str. 10, 13125 Berlin, Germanyiblasig@berlincures.com (I.E.B.)
2 Kings College London, Strand, London WC2R 2LS, UK; paul.fraser@kcl.ac.uk
3 Institute of Biophysics, Chinese Academy of Sciences, Beijing 100049, China
* Correspondence: zhihai@zzu.edu.cn (Z.Q.); reiner@rfh-cns.de (R.F.H.)
† Current Address: The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

21 5 2024
6 2024
25 11 560107 2 2024
10 3 2024
28 3 2024
© 2024 by the authors.
2024
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
This review addresses the role of tight junction proteins at the blood-brain barrier (BBB). Their expression is described, and their role in physiological and pathological processes at the BBB is discussed. Based on this, new approaches are depicted for paracellular drug delivery and diagnostics in the treatment of cerebral diseases. Recent data provide convincing evidence that, in addition to its impairment in the course of diseases, the BBB could be involved in the aetiology of CNS disorders. Further progress will be expected based on new insights in tight junction protein structure and in their involvement in signalling pathways.

tight junction proteins
blood-brain barrier
tight junction structure
cerebral disease
claudins
occludin
This research received no external funding.
==== Body
pmc1. Introduction

Endothelial and epithelial cells separate tissues from each other and from internal and external influences by regulating the fluxes of solutes and xenobiotics; their function is indispensable to life in higher organisms. The plasma membranes of neighbouring cells are linked, so restricting lateral diffusion results in polarised cells with polarised membranes, thus generating structural and functional differences in their apical and basolateral portions [1].

Cell-cell contacts consist of tight junctions (TJs), adherens junctions, gap junctions, and (in epithelia only) desmosomes [2]. The TJ function is essential for tissue borders, such as those in the liver, kidney, or brain. Adherens junctions (AJ) are formed by cadherins [3] and stabilise intercellular contacts by connecting adjacent cytoskeleton arrays [4]. AJ are involved in the development and maintenance of cell barriers [5] and support the formation of TJs [4]. TJs and AJs form mixed contacts in endothelia, are largely indistinct in the brain [6] (whilst appearing separate in most epithelia), and are termed the apical junctional complex [7]. In gap junctions, connexins establish intercellular channels that provide intercellular communication and coordination by exchanging ions, messengers, and small metabolites [8].

Tissue barrier function is also determined by paracellular channels, influx and efflux transport systems, transcellular pathways, metabolic regulation, and by the cellular neighbourhood. Individual barriers vary considerably in tightness and molecular selectivity depending on the expression of junctional proteins and permeability factors. The presence of TJs is the principal determinant of barrier and passage mechanisms. The exact mode of interactions of TJ proteins and their involvement in signalling pathways is far from being well understood. The processes that determine the balancing of tightness and selective permeation will be discussed to contribute to a better understanding of normal barrier function and barrier-related pathologies. This review focuses on transmembrane TJ proteins, on their structure, expression, regulation, and interactions in tissue borders. The principles are exemplified by well-studied brain barriers, in particular the blood-brain barrier (BBB, Figure 1). In this context, we also address TJ protein modulators and their potential pharmacological use.

2. Tight Junctions: Proteins, Functions, and Structures

Tight junctions (TJs) are apical cell contacts (Figure 1B) formed from protein strand networks between neighbouring plasma membranes [2] (Figure 2B). These strands appear in freeze fracture electron micrographs as closely spaced particles (diameter ~10 nm, Figure 3) which, in some tissues, provide a seal against ions, proteins, immune cells, and toxic or pharmaceutical compounds [10,11,12]. In many epithelia and endothelia, the TJ configuration allows a size- and charge-dependent paracellular diffusion for molecules or ions [13,14]. For example, in the brain, the blood-brain barrier is much denser than the blood-cerebrospinal fluid barrier [15]. Similarly, the epithelium in the renal tubule system varies considerably from leaky proximal tubules to the tight loop of Henle and collecting ducts [16]. The TJ network is arranged similarly to a belt in adjacent cell membranes (Figure 2B). The transmembrane proteins of the TJs (Figure 2D) provide the basis for differences in apical and basolateral membrane composition [17] (membrane polarity), which limits the lateral diffusion of lipids and proteins [18]. Moreover, in addition to their sealing function, TJs contribute to the regulation of cellular proliferation and differentiation [19].

There are more than 30 transmembrane proteins that are involved with TJ composition, including members the claudin family [20,21], TJ-associated MARVEL proteins (TAMPs) [22], and junctional adhesion molecules (JAMs) [23]. They are connected to intracellular structures via a number of cytosolic adaptor proteins, such as the zonula occludens (ZO) proteins [24], which provide a link to the cytoskeleton (Figure 2D). JAMs and ZO proteins alone do not form TJs. The transmembrane TJ proteins are subject of continuous turnover, in most cases via clathrin-mediated endocytosis [25,26], caveolin [27], or macropinocytosis [28] with subsequent lysosomal decomposition or recycling to the membrane [27,29,30].

Claudins, a multigene family of 27 members with a molecular mass of 20–29 kDa [31] (first described in 1998 [20]), form the key component of the TJs and are essential for paracellular sealing of tissue barriers [13,32] (Figure 2). Based on sequence comparison, claudins can be divided into (homologous) classic and (less homologous) non-classic claudins. A functional distinction can be made between sealers (e.g., claudin-5) and sealers that simultaneously form paracellular channels (e.g., claudin-15). The function of certain claudins is unclear (e.g., claudin-25–27) or described controversially (e.g., claudin-4, Table 1).

Crystal structural data (obtained for claudin-15 [33], -19 [34], -4 [35], and -9 in complex with a toxin [36]) show a bundle of the four transmembrane helices and a joint extracellular domain consisting of a β sheet (five β-strands) and usually two short helices (Figure 4A, Supplementary Figure S1). Two cysteines in the first extracellular loop (ECL1) and the disulfide bridge included therein are part of a consensus sequence (G-L-W-x-x-C-[7–9 polar/charged amino acids]-C) [13,37,38]. In their C-terminal part, many claudins (e.g., Claudin-1–8) contain a conserved binding motif (Y/L/F/P)-x-K/R/L/V-K/R/T/S-x-Y-VCOOH [39], enabling association with the PDZ1 domain of ZO proteins [40,41] (Figure 2D). There are several sites of post-translational modification, e.g., at the conserved Tyr of the PDZ-binding motif (Table 2), that regulate claudin functions, including oligomerisation, transport processes, interactions, subcellular localisation, and homoeostasis [42]. Frequently, tyrosine is phosphorylated at the conserved PDZ binding motif [43]. Cys-palmitoylation at the intercellular loop or at the cytosolic C-terminal portion is essential for building the TJs [44].

The ultimate function of a TJ barrier depends on a number of parameters, such as cell type, tissue, organ, or even species, in addition to the role of any individual claudin and the presence and stoichiometry of other family members. For example, rat cholangiocytes or human-colon-derived Caco-2 cells express a large but considerably different subset of claudins [45]. Claudin-11 is expressed in oligodendrocytes to form the electrical seal of the myelin sheet around nerve fibres and forms the blood-testis barrier in Sertoli cells [46,47]. Claudin-13 has been found in mouse but not, so far, in human tissues (Supplementary Figure S1). The claudin profile is dynamically regulated during development and by environmental conditions (reviewed by refs. [48,49] and others). It should be noted that expression data collected in vitro often differ from those collected in vivo [50], similar to mRNA and protein expression levels. Interestingly, claudins (1, 7) have also been found at the basolateral membrane (but with unknown local function) [51,52].

Figure 3 Freeze fracture electron microscopy of tight junction (TJ) strands. Strand networks between mouse brain capillary endothelial cells. TJ strands on exoplasmic (E-face, EF) and protoplasmic (P-face, PF) fracture of the plasma membrane indicated by arrows. (A) Cell culture model [49]. (B) Isolated brain capillaries [53].

TJ structures are mainly formed via oligomerisation of the extracellular claudin domains of adjacent cell membranes [54]. These trans interactions create—in conjunction with cis associations along the cell membrane (Figure 4B)—TJ strands (Figure 3), which are responsible for paracellular sealing and channel function (Table 1). Certain combinations of heterophilic interactions in cis and trans are preferred, while others do not occur. Claudin-1, -3, and -5 can interact in cis and trans with each other, claudin-2 and -11 only interact with themselves (Figure 4C). Thus, levels of the different claudin subtypes localised at the TJs determine the permeability and specificity of the paracellular pathway [49].

Figure 4 Structural and interaction models of claudins. (A) General model based on crystal structure of claudin (Cldn)-15 ([33], C-terminus truncated by 33 amino acids). ECL1 and -2 form an extracellular domain consisting of a β-sheet (five antiparallel β-strands, blue) and two α-helices (red) and unstructured areas (grey). TM, transmembrane domain; ECL/ICL, extra-/intracellular loop; PM, plasma membrane. (B) Trans interactions between claudins of neighbouring cell membranes and cis interactions along a plasma membrane. Red, conserved residues including two cysteines form an intramolecular disulfide bridge. PDZ, binding motif for PDZ1 domain in zonula occludens proteins. (C) Scheme of different interactions of blood-brain barrier-expressed claudins, occludin, and tricellulin [50,55].

ijms-25-05601-t001_Table 1 Table 1 Claudin (Cldn) functions in tight junctions.

Class	Paracellular Sealing	Function
Paracellular Sealing/Channel-Forming	Other	Not Clear	
classic *	Cldn1 [56]	Cldn2 [57]/(Na+, K+) [58]			
	Cldn3 [59]				
	Cldn4 [60]	Cldn4 [61]/Na+ [62]			
	Cldn5 [63]	Cldn7 [64]/Na+ [65]			
	Cldn6 [66]	Cldn10 sealing/-10a an-, -10b cat+ [67]	Cldn6 [68]		
	Cldn8 [69]	Cldn15 sealing/Na+, K+ [62]			
	Cldn9 [66]	Cldn17 sealing/an- [70]	Cldn9 [68]		
	Cldn14 [71]				
	Cldn19 [72]				
non-classic	Cldn11 [73]	Cldn16 sealing/cat++ [72]	Cldn13 [68]	Cldn12, -13, -20 [50]	
	Cldn18 [74]	Cldn21 sealing/Na+, K+, solutes ≤ 0.56 nm [75]		Cldn22, -23, -24 [50]	
	Cldn25 indirectly [76] via structure of TJ [50]			Cldn25, -26, -27 [50]	
*, high sequence homology [13]; an, anion; cat, cation.

ijms-25-05601-t002_Table 2 Table 2 Characteristics of selected claudins (Cldns) of the blood-brain barrier.

Expression	Function	Structure/Interactions	Regulation/Signalling	
Claudin-1 (Senescence-associated epithelial membrane protein)	
- gene CLDN1, chromosome 3 (human), -16 (mouse)
- protein: human [77,78], mouse [78,79]
- cell membranal at TJs [80] and cytoso-

lic [50] localisation [53]
- KO mouse: postnatal dehydration, lethal [81]	- causes tightness (TER) [56,82], sealing [56,82,83]
- receptor for hepatitis C-

virus [84]	- 211 aa; M.W., 22.7 kDa; pI, 8.41; N-/C-terminal tail, 7/27 aa; ECL1/ECL2, 53/27 aa (human)
- homophilic cis/trans interactions [85,86], dissociation constant ECL1 to Cldn1 47 ± 0.6 nM [86]
- heterophilic cis Cldn3, -5 [87], Ocln, Tric, MD3 [55], PDZ1 of ZO-1 [88]; trans Cldn3,-5 [87], Ocln, Tric, [55]
- continuous P-face TJ-strands [55]
- low membrane mobility [55]	- GPR30 via ERK and/or Akt-domain [89]
- dehydroepiandrosteron/Gnα11 [90]
- hypoxia inducible factor-complex [91]
- cAMP/PKA, down-regulation and cytosolic localisation [92]
- down-regulated by hypoxia, focal cerebral ischemia [50], glioblastoma [93]
- down-regulated by TGFβ [93], Cu [94], miR212/132 [95]
- differentiated regulation upon virus infection [96,97,98,99,100]	
Claudin-3 (Clostridium perfringens enterotoxin receptor 2)	
- gene CLDN3, chromosome 7 (human),

5 (mouse)
- protein: human [77,78], mouse [78,79], rat [101]
- KO mouse: amount of Cldn5 and Ocln, paracellular permeability reduced [53]; no changes found by other authors [102]	- enhances BBB integrity in vivo [78], increases complex-ity of TJ-strand network [53]
- controls paracellular tightness [59,103,104] (particularly small molecules/ions)
- limits endocytosis; pro-motes infarction/oedema [53]
- supports embryogenesis/

postnatal development, stabilises BBB/TJ [105]	- 220 aa; M.W., 23.3 kDa; pI, 8.37; N/C-terminal tail, 8/40 aa; ECL1/ECL2, 51/23 aa (human)
- homophilic interaction cis/trans [87]
- heterophilic cis Cldn1, -5 [87], Tric, MD3 [55], associates ZO-1-PDZ1 [40]; trans Cldn1, -5 [87], Tric, MD3 [55]
- continuous P-face strands [87,106]
- high membrane mobility >Cldn5 [87]
- strengthens TJ strand network/-branching [53]	- Wnt/β-catenin controlled barrier development [105]
- expression modulated by Na/K-ATPase [107]
- down-regulated by hypoxia/middle cerebral artery occlusion [50]
- down (haemorrhage) (PI3K, sphingosine 1-phosphate receptor 1) [104]
- loss in EAE, glioblastoma [78]
- down-regulated at low Cu [94]	
Claudin-5 (Transmembrane protein deleted in velocardiofacial syndrome)	
- gene CLDN5, chromosome 22 (human), 16 (mouse)
- very high expression [50,78,108], embryonically starting with cerebral angiogenesis [109]
- KO mouse: abnormal TJs, brain capillaries permeable for molecules < 800 Da, lethal 10 h postnatally [63]
- KD: BBB breakdown in tissue culture, human BEC [110]
- t1/2 70 min [111]
- protein amount: Cldn5 > −25, Ocln, Cldn1 > −11, −12 (isolated brain capillaries, TX-100 extract) [50]	- causes paracellular tightness for molecules < 800 Da [63]
- induces/maintains TJ tightness [21,112] mediated via ECL1 [113] and ECL2 [54]	- 218 aa; M.W., 23.1 Da; pI, 8.25; N-/C-terminal tail, 7/38 aa; ECL1/ECL2, 53/16 aa (human)
- homophilic cis/trans interaction [54,87]
- heterophilic cis Cldn1, -3 [87], Tric, MD3; trans Cldn1, -3, Ocln, Tric [55]
- discontinuous E-face-associated TJ-strands (in TJ-free cells) [21,54]
- low membrane mobility [87]
- mixed E-/P-face strands by Cldn3 [87]
- associates ZO-1-PDZ1 [40]
- no effect on ZO-1 clustering [114]
- C54S, C64S (mouse ECL1, aa exchange)

weaken barrier [113]
- ECL1-G60R, human channelopathy: Cl-/small molecule flux [115]
- transferred from BEC to leukocytes in EAE, possibly supporting transmigration into CNS [116]	- Thr(207)-phosphorylation opens porcine BBB, protein kinase A [117]
- TGF-β/activin signalling increases Cldn5 [118]
- VE-cadherin via Akt-activation: phosphorylation of FoxO1 induces Cldn5 [119]
- adrenomedullin: enhanced expression and TER, decreases permeability [112]
- increase (mRNA, protein, promoter): gluco-corticoids TER up [120,121], estrogen [122]
- ROCK via EphA2: down-regulation [123]
- ROCK up in dementia: Cldn5 down [124]
- C/EBP-α (stimulated by JAM-A) up-regulation, reduced permeability [125]
- serum Cldn5 up: autistic children [126], severe stroke [127]
-down-regulated by EphA4/Tie2/Akap12 signalling mediating microvascular dysfunction and trauma [128]
- down-regulated at low Cu [94]
- oxidative stress inhibitor improves Cldn5, ZO-1, TER via Nrf2/HO-1 [129]	
Claudin-11 (Oligodendrocyte-specific protein)	
- gene CLDN11, chromosome 3 (human), 3 (mouse)
- mRNA/protein: very high expression

in BEC (human, mouse, rat) in vivo equal to Cldn5, in vitro strongly down-regulated [50,130]
- less expressed in human brain oligodendrocytes [50]
- KO mouse: mild neurological deficits [131], deafness (low endocochlear potential) [47]
- KD: enhanced dextran permeability through BEC layers [130]	- contributes to tightness of BEC layers [50,130] and BBB [132]	- 207 aa; M.W., 22.0 Da; pI, 8.22; N-/C-terminal tail, 1/29 aa; ECL1/ECL2, 50/14 aa (human)
- very strong homophilic cis/trans interaction (Cldn11 >> other Cldns, Ocln, Tric [55,133])
- no heterophilic binding [55]; Cldn5 colocalisation in junctions [50,130]
- continuous P-face oriented TJ-strands, modulated by Ocln [50]
- very low membrane mobility <other Cldns [50], Ocln, Tric, MD3 [55]	- reduced in multiple sclerosis [130]
- decreased in EAE by activated annexin A2 signalling (brain capillaries) [134]
- decrease in BEC by podocalyxin KD [135]
- increased in blood of human autism spectrum disorder [126]
- ischemia reduces Cldn11; KO of leucine-rich alpha-2 glycoprotein 1 improves Cldn11 and BBB in ischemia [132]	
Claudin-12	
- gene CLDN12, chromosome 7 (human), 5 (mouse)
- in BEC [63,94,136]; mRNA in vivo > in vitro [50]
- expressed at TJs [50,63]
- lack of Cldn12: intact BBB; neurological/behavioral changes [137]
- knock-in mouse: mRNA in BEC, pericytes, oligodendrocytes, smooth muscle cells, astrocytes [137]	- not crucial in establishing or maintaining BBB TJ integrity [137]	- 244 aa; M.W., 27,1 kDa; pI, 8.80; N-/C-terminal tail, 10/49 aa; ECL1/ECL2, 56/18 aa (human)
- homophilic: no cis- [87], but weak trans interaction [55]
- heterophilic: weak trans interactions with Cldn22, -24, -25, Ocln [50]
- no C-terminal PDZ-binding motif [87]
- no strand formation [87], very high paracellu-lar flux in TJ-free cells [138]	- ouabain-activated Na/K-ATPase reduces expression [107]
- high-energy diet decreases mRNA-, increases hippocampal permeability [139]
- hyperammonia reduces mRNA in vitro [140]
- down-regulated in hypoxia/ischemia [50,53] and in diet-induced diabetes (in latter case attenuated by carbonic anhydrase inhibitor [141])
- regulated by Cu exposure [94]	
Claudin-25 (Claudin domain-containing protein 1)	
- gene CLDND1, chromosom 3 (human), 16 (mouse),
- very high mRNA expression in vivo in BEC [50]
- in human BEC localised at TJs [76]
- KD: reduces mRNA/protein without cytotoxicity, paracellular permeability raises for small molecules [76]; P-face strands less structured, reduced mesh number, i.e., less particles, larger meshes] [50].	- contribution to cell adhe-sion and tightness for small molecules [76]	- 229 aa; M.W., 25.4 Da; pI, 5.37; N-/C-terminal tail, 10/44 aa; ECL1/ECL2, 50/19 aa (human)
- no homophilic trans interaction in BEC [50]
- weak heterophilic trans interaction (Cldn12, -22, -24, Ocln) [50]
- no TJ strand formation, but strands supported indirectly (via Ocln) [50]	- xenobiotics-activated arylhydrocarbon-receptor [142], retinoic acid receptor-related orphan receptor α [143], and myeloid zinc finger 1 [144] increase mRNA expression
- transcription inhibition by miR-124 [145]
- cerebellar haemorrhage decreases expression in mouse BEC by [76]	
aa, amino acids; Akt, protein kinase B; BEC, brain endothelial cells; BBB, blood-brain barrier; Cldn, claudin; C/EBP, CCAAT/enhancer-binding protein; cis interaction, cf. Figure 4B; EAE, experimental autoimmune encephalitis; E-face, exoplasmic-face; EphA2/4, ephrin type-A receptor 2/4; ERK, extracellular-signal regulated kinase; ECL, extracellular loop; FoxO1, forkhead box O1; G, G-protein; GPR, G-protein-coupled receptor; JAM, junctional adhesion molecule; KO/KD, knockout/-down; MD3, MarvelD3; M.W., molecular weight; Nrf2/HO-1, erythroid 2 like 2 nuclear translocation/haem oxygenase 1 signalling; Ocln, occludin; PI3K, phosphoinositide 3 kinase; P-face, protoplasmic-face; pI, (calculated) isoelectric point; PK, protein kinase: ROCK; Rho-associated protein kinase; t1/2, half-life; TER, transendothelial electrical resistance; TGF, transforming growth factor; TJ, tight junction; trans interaction, cf. Figure 4B; Tric, tricellulin; ZO-1, zonula occludens protein 1.

3. Tight Junctions and Their Proteins at the Blood-Brain Barrier

The BBB ensures the brain function by maintaining a constant cerebral milieu and is thus a decisive factor for the homoeostasis of the CNS. It provides a highly efficient exchange of nutrients and metabolites and prevents the permeation of xenobiotics, peripheral metabolites, pathogens, and blood cells [146]. The BBB is formed by capillary endothelial cells (Figure 1B and Figure 2A) influenced by the basal membrane, pericytes, (located within the basal membrane), neurons, microglia, and especially astrocytes. The whole ensemble is referred to as the neurovascular unit (Figure 1A). Pericytes surround a third of the endothelium [147] and support the formation and maintenance of the BBB. They contribute to angiogenesis and various brain functions. Microglia provide the immune defence of the brain by being activated under pathological conditions [148,149]. The endfeet of astrocytes almost completely envelop the capillaries [147], which is highly important for a functional BBB [150]. The capillaries exhibit an inner diameter of 3–5 µm. In humans, the capillary system has a total length of ~650 km and a surface of 10–20 m2 [151,152,153]. The cleft between the endothelial cells is closed by an intercellular network of TJ strands, preventing direct diffusion of solutes including Na+, K+, and water [154,155,156] (Figure 2B and Figure 3). Water transport is probably mainly diffusive since the measure of hydraulic conductance of 2 × 10−9 cm (cmH2O s)−1 is comparable to that of endothelial cell membranes [157].

The very high TJ density of the BBB results in a considerable transendothelial electrical resistance (~5 kΩcm2) as it lacks paracellular channels, as seen for other barriers [158] such as the blood-cerebrospinal fluid barrier (where claudin-2 creates ion channels [15]). Flux rates through the BBB are very low for hydrophilic molecules for which transporters are lacking [159]. The barrier function is supported by low pinocytosis, little vesicular transport, and no fenestration in the cells [146,160]. The supply of the brain with substrates and regulatory molecules is enabled by selective transport systems, which are essential because the paracellular route is blocked by TJs. The TJs are thus the key element of the BBB [161,162,163]. Additionally, a metabolic barrier is formed by the high activity of endothelial enzymes, such as γ-glutamyl transferase, alkaline phosphatase, glucose-6-phosphatase, catechol-O-methyl transferase, monoaminoxidase, or cytochrome P450 [164]. They collectively prevent their substrates passing into the CNS owing to their being metabolised during entry into or within the cell.

In general, TJs largely prevent passive paracellular diffusion of polar compounds, thus mandating diffusion across the plasma membrane and cytosol (O2, CO2, lipophilic molecules with molecular masses <500 Da, e.g., ethanol [165]). Other molecules require transporters or paracellular channels. For endothelial cells of the BBB, this includes cerebral Na+-uptake (indirectly that of water), extracellular HCO3− (pH), and the maintenance of interstitial K+-concentration (Na+, K+-ATPase) in the brain [166]. Thus, the TJs allow for a number of electrochemical gradients to be established, and these provide the driving force for the transport of substances that maintain homoeostasis of the CNS. Special transporters also exist for hydrophilic substrates such as glucose, amino acids, lactate [167,168,169], neuropeptides [170,171], and biotransformed products [172]. Receptor-mediated transcytosis via the use of specific carrier proteins facilitates intake of macromolecules as insulin [173], LDL [174], transferrin [175], leptin [176], and others [177]. Additionally, TJs render efflux transporters barrier-effective by excluding small (400–600 Da) lipophilic/non-charged compounds from the brain, amounting to more than 300 metabolites, toxins, and drugs [178,179,180,181] (Figure 1C).

3.1. Claudins

Claudins 1, 5, 11, 12, 25, 27 (only human), and 20 (only mouse) are abundantly expressed in capillary endothelial cells of cerebral cryosections (mRNA). Claudins 2–4, 6, 9, 15, 17, 22, and 20 and 23 (both only human) and 14, 24, and 26 (only mouse) are less abundant [50] (Figure 5). The mRNA values roughly reflect the protein values [50,63]. Consequently, the highly abundant claudins 1, 5, 11, 12, and 25 are discussed below, while the less-abundant claudin-3 is also discussed since a number of reports suggest that it plays a role in BBB pathology [50,53,78,104,105,182] (Table 2).

Claudin-5, a tightening claudin and highly expressed [183,184], is most important for very dense TJs [158] in vertebrate BBBs [63,185]. It tightens the barrier (two-cell- or two cell(-like) contacts, Figure 2A, left) for molecules < 800 Da [63], which includes the majority of physiologically active substances. The paracellular cleft is closed via tight cis and trans interactions of the extracellular domains [115,186]. A hereditary mutation in loop 1 results in a severe channelopathy with the increased permeation of ions and small molecules [115]. These data support the great relevance of claudin-5 for the pharmacology and pathology of the BBB. Its knockdown up-regulates claudin-1 [50], pointing to a compensatory potential between sealing claudins. ZO-1 [40] and occludin [55] interact with claudin-5 and facilitate the formation of claudin-5 strands [41,55]. On the other hand, the clustering of ZO-1 is independent of Claudin-5 [114]. As visualised by freeze fracture electron microscopy, claudin-5 alone assembles in exoplasmic TJ strands [54,187]. Freeze fracture EM of mouse cerebral endothelium shows that these strands also appear on the protoplasmic surface [188] (Figure 3), which indicates that additional strand-building proteins are sufficiently expressed. In primary cultures of human brain endothelial cells, claudin-5 has a half-life of 13.8 h [189]. The trafficking is caveolin-dependent [26,27], and it is either recycled [27,30] or ubiquitinylated and degraded in the proteasome [42,111], indicating high protein dynamics.

Claudin-11, another sealing [50,130,190] protein, forms strands associated with the protoplasmic face [50], interacts only in a homophilic manner [55,133], and is almost exclusively detectable in vivo [50,133]. The protein level is comparable to that of claudin-5 [130]. Claudin-11 has a much higher homophilic affinity than claudin-5 [55], resulting in a considerably reduced membrane mobility. It can be found in distinct TJ segments being free of other claudins [50]. Molecular modelling indicates a relatively small extracellular binding domain (Supplementary Figure S1). This, combined with a strong capacity for oligomerisation, low junctional agility, and no interrelations with other claudins, suggests a very tight intercellular seal. Occludin indirectly modulates claudin-11 strand morphology [50]. Knockdown in brain endothelial cells decreases paracellular tightness [50,130]. Mild neurological deficits have been described in claudin-11 (also known as oligodendrocyte-specific protein) knockout mice, since its function in the myelin sheath is partly substituted by another structurally similar membrane protein [1,131]. Claudin-5 and -11 seem to act partly synergistically, and seem to compensate for each other; claudin-5 deficiency does not lead to a complete loss of sealing [63]. Their exoplasmic and protoplasmic strand orientations also complement each other.

Claudin-12 is well expressed in endothelial cell contacts both in brain sections [63] and in purified brain capillary endothelial cells [136]. Claudin-12 does not, however, form TJ strands [87], probably due to its lack of homophilic cis interaction and a lack of the C-terminal PDZ-binding motif that prevents association with the PDZ1 domain of ZO-1 [40], which usually supports TJ formation [191]. Additionally, this claudin shows weak homo- and heterophilic [55] trans oligomerisation with claudin-25 and occludin. These interactions could help to maintain the support of claudin-25 for TJ strand morphology [50] or to preserve the TJ regulation by occludin [192], and it appears that claudin-12 plays a role in the maintenance of the BBB as it has been shown to be down-regulated under pathological or toxicological conditions [50,94,107,139,140,141].

Similarly, claudin-25 is highly expressed and its contribution to barrier function is unclear; it does not show homophilic trans interaction, which limits its potential for direct barrier sealing and TJ formation. Claudin-25 does localise at cerebral endothelial cell contacts and indirectly supports a functional TJ morphology. This is probably due to trans interactions with occludin [50], a main regulator of BBB TJs [192] under normal [156] and pathological [193] conditions. Its importance in TJs is demonstrated by claudin-25 knockdown, leading to the hyperpermeability of small molecules and weakening the TJ strand network in an in vitro BBB model [50]. Since claudin-25 interacts with occludin but not with strand-forming claudins, it probably indirectly contributes to TJ function. N-Glycosylation at the extracellular loop 1 of claudin-25 [194] promotes its localisation at the plasma membrane and can initiate signal transduction processes [195]. Hence, claudin-25 can be considered as a TJ modulator at the BBB.

Claudin-1 and -3 form strands associated with the protoplasmic face and are frequently involved in sealing of epithelial barriers. Their function at the BBB is not clear, their interaction potential with claudin-5, occludin, and tricellulin renders both as candidates for tightening the BBB. Claudin-1 is also considered in a developmental context [196]. Its immune reactivity is often observed as more cytosolic than junctional [50] and its deficiency does not show a cerebral phenotype [197], but overexpression has a tightening effect at the BBB [83]. The low mobility [55] correlates with strong homophilic affinity [86]. Application of claudin-1-derived peptides that block its interactions leads to higher permeability of cerebral endothelial barriers [198]. The high affinity to various interaction partners [87], including occludin [55] and its redox sensitivity [86,91,94], point to a modulatory role in corresponding pathologies.

The expression of claudin-3 at the adult BBB is rather low [50,94], and its significance for the barrier is questioned [102]. Claudin-3 knockout experiments, however, result in reduced claudin-5 expression, lower junctional occludin localisation, and increase branching of TJ strands. The strand network is weakened, and barrier permeability increases, which diminishes the infarct area and oedema formation in a stroke model [53]. This supports the idea that to attenuate ischemia-related damage (e.g., oedema) via TJ modulation using claudin inhibitors could open the BBB reversibly [199]. Changes of claudin-3 at the BBB are found in experimental ischemia/reperfusion [50,53], haemorrhage [104], and chronic inflammatory pain [182] in a multiple sclerosis model (experimental autoimmune encephalitis [130]) or in human glioblastoma multiforme [78]. Moreover, claudin-3 is involved in the development and maintenance of the BBB [105]. Thus, a role in barrier regulation is assumed, which would be supported by its high membrane mobility [87] and its interaction with other claudins and occludin [55].

In summary, claudin-5 is considered the major component of the TJs and, for small molecule tightness, the essential sealer of the BBB; claudin-11 also seals the barrier and partially compensates for claudin-5. Claudin-3 might have a limited contribution to TJ function and could be involved in pathological processes. Claudin-25 does not contribute to the structure and function of TJs directly but could modulate it indirectly. The function of claudin-12 remains unclear.

3.2. Tight Junction-Associated MARVEL Proteins

Table 3 characterises structure, function, and regulation of the TJ-associated MARVEL proteins (TAMPs) expressed at the BBB, i.e., occludin, tricellulin, and MarvelD3 (expression of the latter reported only once so far [200]). Occludin localises mainly in two-cell contacts [201]; it is found ubiquitously in TJs and is often used as a TJ marker protein [202]. Tricellulin (in particular, tricellulin a), is expressed with markedly lower total expression level (Figure 5, dashed box) [50] but is highly enriched in tricellular contacts [203] (Figure 2C). TAMPs show four transmembrane domains, cytosolic termini, one intra-, and two extracellular loops [22] (the second containing a conserved intramolecular disulfide bridge [133,204]. The MARVEL (MAL and related proteins for vesicle trafficking and membrane link) domain comprises all transmembrane domains and loops [205] (Figure 2D) that form cholesterol-rich microdomains in plasma membrane appositions [206]. The TAMPs are involved in the formation of TJs [207,208] by interacting with claudins, but occludin and tricellulin do not bind each other [55], although they support TJ-strand branching and stabilise epithelial barrier integrity [209]. Tricellulin may also occur at bicellular contacts [210] and can partially compensate for occludin [22], thus contributing to paracellular tightness [211]. Occludin and tricellulin are redox-sensitive and regulate bicellular and tricellular TJs under oxidative or reducing conditions [133,204].

The exact function of occludin is still unclear. There is no evidence for a direct barrier function [212,213], although heterophilic and homophilic oligomerisation do occur [55,204], the latter via its cytosolic C-terminal coiled-coil domain [214]. This domain is involved in macromolecule flux through TJ barriers [215], ZO-1 association [215,216], and their proteins are targets of various protein kinases [217,218]. Multiple phosphorylation [202] is demonstrated via a molecular weight shift in electrophoresis [219]. These and other modifications [220] are mediated by different signalling pathways (relevant for normal and pathological conditions) and strongly point at a regulatory function, e.g., via interaction with claudins and/or ZO proteins (Figure 2D) [205]. The number of studies that exploit these pathways for new medical applications is increasing [141,221]. There is wide agreement that occludin is involved in the regulation of the TJ permeability [212,222].

Tricellulin fulfils its general function, sealing the gap at the contact points (Figure 2C) of three membranes. In the BBB, primarily single endothelial cells form distinct capillary segments by themselves; thus, three separated membrane patches from two different cells meet in one point (three-cell-like contacts, Figure 2A, right) [203,223]. The protein oligomerises homophilicly, creates tricellular TJs [133], and tightens this area (in epithelial cells) for molecules < 10 kDa without affecting ion permeability [211]. Comparing bi- and tricellular contacts, it is concluded that the expressed amount of sealing TJ proteins (claudin-5 and -11) in bicellular TJs is about two orders of magnitude higher than that of tricellulin [50]. This suggests that the BBB function is quantitatively determined by two-cell TJs, which prevent permeation of small and large molecular weight compounds [63], rather than by tricellular TJs that withhold larger molecules [211,224].

In three-cell(-like) contacts of brain endothelial cells, tricellulin specifically concentrates and colocalises with angulin-1/LSR (lipolysis-stimulated lipoprotein receptor) [203], a type I transmembrane protein with a single Ig-like domain [225]. Tricellulin and angulins form so-called central sealing elements [226] laterally in three-cell(-like) contacts (Figure 2C). For delivery of antisense oligonucleotides (5.3 kDa) through the BBB, these TJs can be modulated by recombinant angubindin-1, a Clostridium perfringens iota-toxin, which binds to angulin-1 [224]. Angulin-1 knockout mice exhibit embryonic lethality [227] with BBB failure [228], which is not known from tricellulin deficiency. These and other observations support the assumption that angulin-1, and not tricellulin, could be essential for sealing the three cell-like contacts in cerebral capillaries. In epithelial cells, angulin-1 forms tricellular contacts, even in tricellulin- or claudin-deficient cells [229].

ijms-25-05601-t003_Table 3 Table 3 Tight junction-associated MARVEL-proteins (TAMPs) expressed at the blood-brain barrier.

Expression	Function	Structure/Interactions	Regulation/Signalling	
Occludin	
- gene OCLN, chromosome 5 (human), -13 (mouse)
- expression < Cldn5 [50]
- increased expression in co-culture of BEC with astro-/pericytes [230], neurons
[231]
- half-life 6.2 h [189]
- KO mouse: TJ-morphology unchanged, calcification of brain [212]
- Ocln/Tric-double KO:
lowers TJ-strand branches/
barrier integrity [209]	- TJ-regulation postulated [192]
- redox sensor in TJs [204]
- facilitates TJ branching/barrier tightness [55,209]
- C-terminal CC-domain required for maintenance and regulation
of macromolecule flux through
TJs [215]
- regulates centrosomes in cortex genesis [232]
- regulates apoptosis via
caspase-3 transcription [233]
- controls HIV-transcription [234], glucose uptake/ATP-synthesis [235] of BBB pericytes
- Ocln/caveolin-1/Alix-complex regulates HIV-permeation
through BBB [192]
- required for cytokine-mediated signal transduction [236]	- human: 522 aa; M.W. 59.1 kDa (polyphosphorylated ≤ 65 kDa [219]); pI 5.77
- cytosolic N-/C-termini 66/257 aa; ECL1 46 aa (11 Tyr, 19 Gly—potentially hydrophobic interactions, flexibility); ICL 11 aa; ECL2 48 aa (2 Cys, disulfide bridge, hypoxia-/redox-sensitive) [204]
- interactions: homophilic trans, cis (CC do-
main dimerises [214]); heterophilic cis Cldn1, MD3/trans Cldn1, -5 [55], -25 [50]
- 3D-structures: cytosolic C-terminal region [237], complex ZO-1 (PDZ3-SH3-U5-GuK)/
Ocln (CC-domain) [222]
- CC-domain binds ZO-1 (SH3-hinge-GuK) [216], possibly interacts with ZO-1 [215]
- peptide sequence of CC-domain associates PKC ζ, Tyr-kinase c-Yes, PI3K, connexin 26 [218]
- MARVEL-domain: in membrane appositions, cholesterol-rich microdomains [206]; mediates interaction of TJs with membrane lipids, cis-oligomerisation via Cys and membrane insertion [238]	- Tyr398, Ser408: high-conserved phosphorylation sites for PKCs, CK2, Tyr-kinase Src [217]
- thrombin: Tyr-phosphorylation, Ocln-ZO-1-/TJ disruption, BBB leakage; angiopoietin-1 inhibits this Tyr-phosphorylation, stabilises TJs [239]
- VEGF-activated atypical PKC opens BBB [240]
- VEGF/hypoxia activate PLCγ, PI3K/Akt, PKG: rearrange Ocln, ZO-1, -2; open BBB [241]
- EGFR-activation: p38 MAPK/NFκB signal pathway reduce Ocln expression [242]
- ubiquitinated by E3A Nedd4-2 [243]/Itch [244] (prevented by γ-secretase blockade [245]
- KD of E3A MARCH3 tightens BEC barrier, induces Ocln-/Cldn5 by FoxO1 deactivation [246]
- reduction: TGF-β via MMPs [93], IL-17 [247]
- degradation: MMP [248,249], calpain (Zn2+-dependent) [250], proteasome [244,251]
- microwave radiation: reduced Ocln/Ocln-ZO-1 binding, TJ broadening/fracture, BBB opening (VEGF/Flk-1-ERK Tyr-phosphorylation mediated) [252]
- ischemia/reperfusion: Ser490 phosphorylation/
ubiquitination via VEGFR2 [253]
- Netrin-1 protects BBB, activates Kruppel-like factor 2/Ocln path (ischemia/reperfusion) [221]
- hypoxia: MMP9 caused Ocln rearrangement in TJs, BBB leakage [254]
- diet-induced diabetes: Ocln/ZO-1 down, BBB leak; lessened by carboanhydrase inhibitor [141]
- autistic children: serum Ocln increase [126]	
Tricellulin (MARVEL domain-containing protein 2)	
- gene MARVELD2, chromosome 5 (human), 13 (mouse)
- particular isoform Tric a [50]
- expression <Ocln, <<Cldn5 [50]
- brain [223], retina [203,255]
- membranal in tricellular [256], bicellular cell contacts [257], likewise nuclear, perinuclear localised [223]
- KO mouse: hearing loss, degenerated cochlea hair cells [258]
- Tric/Occl-double KO lowers TJ-strand branches/
barrier integrity [209]	- sealing of macromolecules but not ions in tricellular TJs [211]
- regulates H2O-permeability
[259]
- role in regulating blood-cerebrospinal fluid barrier [255]
- facilitates TJ branching/barrier integrity [55,209]
- redox-regulation in TJs [260]	- mouse: 558 aa, M.W. 64.2 kDa; pI 7.21
- cytosolic N-/C-terminal 194/196 aa; very
short ECL1/ECL2 8/16 aa; ECL2: disulfide bridge, hypoxia-/redox-sensitive [260]
- homophilic: cis interaction in 2- and 3-cell
TJs; trans in 3-cellular TJs [55,260]
- heterophilic interaction: cis Cldn1, -3, -5,
MD3; trans Cldn1, -5 [55]
- continous P-face strand network in 3-cell TJs [260]; intensifies Cldn1 TJs [55]
- C-terminal CC-domain: crystal structure (2.2 Å), dimer with polar interface [261]
- angulins bind/recruit Tric in TJs [225]
- N-terminus associates dynamin-binding protein (=scaffold protein Tuba) [262], human plasminogen [263]	- ubiquitination by Itch [264]
- MAPK-, PKC-activation causes nuclear localisation in weakly differentiated tissue [265]
- toxin ESX-1 secretion-associated protein EspG1 reduces expression [266]
- induction by mirRNA-203 (microRNA binding motif on Tric) inhibitor, weakening Pb-induced blood-cerebrospinal fluid barrier leak [255]
- down-regulated: interleukin-13 (via IL-13-receptor α2) [267], choleratoxin [268]
- degradation: by MMP2/3 [269]
- apoptosis: degraded at Asp487, Asp 441 (C-terminal CC-domain, caspase cleavage) [270]
- OGD: Tric down in BEC [200]
- increase in cortex: autism spectrum disorders (Cldn3, -5, -12) [271]	
MarvelD3 (MARVEL domain-containing protein 3)	
- gene MARVELD3, chromosome 16 (human)
- KD retards TJ formation [22]	- may partially replace Ocln, Tric [22]	- human 401 aa, M.W. 44.9 Da; pI 8.84; ECL1/2 24/39, N-/C-terminal 226/39 aa
- cis binding: MD3, Ocln, Tric, Cldn1, -5 [55]	- down-regulated by OGD in bovine BEC [55]	
aa, amino acid; BBB, blood-brain barrier; BEC, brain endothelial cell; CC, cytosolic C-terminal coiled-coil (OCEL, ELL) domain; cis interaction, cf. Figure 4B; CK, casein kinase; Cldn, claudin; EGFR, epidermal growth factor receptor; ECL/ICL, extracellular/intracellular loop; E3A, E3 ubiquitin ligase; FoxO1, forkhead box O1; KO/KD, knockout/-down; MAPK, mitogen-activated protein kinase; MARVEL, MAL and related proteins for vesicle trafficking and membrane link; MARVEL-domain, transmembrane domain 1–4, ECL1, ICL, ECL2; MD3, MarvelD3; MMP, matrix metalloproteinase; M.W., molecular weight; NFκB, nuclear factor κB; Ocln, occludin; OGD, oxygen/glucose deprivation; P-face, protoplasmic face; pI, isoelectric point; PI3K, phosphoinositol 3-kinase; PK, proteinkinase (PKB/Act, PKC, PKG); PL, phospholipase; TGF, transforming growth factor; TJ, tight junction; trans interaction, cf. Figure 4B; Tric, tricellulin; VEGF(R), vascular endothelial growth factor (receptor); ZO-1, zonula occludens protein 1.

3.3. Junctional Adhesion Molecules

The JAMs belong to the immunoglobulin superfamily [272], form one transmembrane domain, and are connected to the cytoskeleton via the binding of their short C-terminus to the PDZ3 domain of ZO-1 [273]. The N-terminal extracellular domain contains two immunoglobulin-like loops which can interact homo- and heterophilically in cis (with proteins of the same endothelial cell) or trans (e.g., with proteins on blood cell proteins) [272,274,275] (Figure 4B). Mainly JAM-A (JAM-1) [276], JAM-C (JAM-3) [277], and the endothelial-cell-selective adhesion molecule (ESAM) are found in TJs of the BBB [278,279] and support barrier features. JAM-A binds to integrin α-V β3 in cis [280] and integrin α-L of leukocytes in trans [281], and JAM-C binds to integrin α-M (trans, leukocyte) [282]). JAMs support the correct localisation of other junctional proteins (e.g., claudins) at the TJs [283] and stabilise cell barriers [284]. They are also involved in the regulation of cell contact formation, cellular migration, and mitosis, and, in this way, take part in barrier formation, angiogenesis and cerebral homoeostasis [285]. JAM-A regulates barrier properties by promoting the expression of C/EPB-α, a transcription factor regulating claudin-5 [125]. ESAM seems to be involved in the endothelial tube formation [286] (Figure 2A), as well as in the extravasation of white blood cells [287]; however, deactivation of the ESAM gene does not change the vascular permeability in mouse brain [288].

3.4. Cytosolic Tight Junction-Associated Proteins

The guanylate kinase homologous (MAGuKs [289]) ZO-1 (TJP1, 225 kDa [290]), as well as N-terminally truncated ZO-2 (TJP1, 160 kDa [291]) and ZO-3 (TJP3, 130 kDa [292]), are the most important membrane-associated proteins on the cytosolic TJ sides in the BBB. ZO proteins are involved in the formation and function of adherens- [293] and gap junctions [294]; consequently, ZO-1 is often used as cell contact marker [50]. In addition, ZO proteins are included in the regulation of cytoskeletal organisation, the establishment of cell polarity, and signalling to and from the nucleus [24]. They constitute the scaffold of TJs via multiple binding areas (in ZO-1: NH2PDZ1–PDZ2–PDZ3–SH3–hinge region–GuK–acidic region–U6 region–proline rich region–ZU5 regionCOOH, Figure 2D). These sections recruit transmembrane TJ-proteins and associate signalling- and structural proteins which, in turn, are involved in the formation, regulation, and/or stabilisation of TJs [295]. PDZ1 associates with claudins, and PDZ2 mediates the dimerisation of ZO proteins and may provide a structural basis for the association of claudins, namely, the formation of TJs [191,296]. PDZ3 and SH3-hinge-GuK bind JAMs and occludin, respectively [216]. SH3 interacts with ZONAB [297]. The hinge region (U5) attracts G-proteins [298], enabling a wide diversity of G-protein-coupled receptors to regulate the BBB [299]. Part of the proline-rich region (amino acids 1151–1371 of ZO-1) allows for the anchoring at the actin cytoskeleton [300]. Nuclear localisation of ZO proteins plays a further role in the signalling of TJ proteins [301,302] (Figure 2D). ZO-1 and ZO-2 can compensate for each other; only double knockdown leads to changes in the localisation of claudins and occludin, resulting in paracellular leakage [293,303,304].

Another scaffolding protein of the apical junctional complex is afadin (AF-6, gene AFDN, a multidomain protein with one PDZ, binds JAM-A). It interacts N-terminally with membranal adhesion- and signalling proteins while its C-terminus binds to the actin filament and to actin-binding proteins. Afadin can modulate signalling processes that influence cellular migration, invasion, and apoptosis [305]. Afadin is expressed at the cerebral endothelium [306] and contributes (in cooperation with PI3K/Akt signalling) to neovascularisation [307]. The cellular polarity at the TJs is maintained by the apical polarity complex, which includes the PAR complex (PAR3, PAR6, aPKC [308]) and the basolateral scribble complex (scribble, DLG, LGL). These complexes form networks via several signalling pathways (e.g., small GTPases as RhoA, RAC, and CDC42 [309]; Wnt/β-catenin [310]); their disbalance leads to perturbations in the barrier function [311]. aPKC and RhoA [283], as well as the PDZ-free scaffolding cingulin-like protein 1 (gene JACOP) [312], are involved in the regulation of the endothelial TJ conglomerate.

Summarising the data of the differentiated BBB, claudin-5 is proven to be the most prominent TJ component that bicellularly seals the barrier, probably assisted by claudin-11. The proper morphology and function of the TJ strand network is facilitated by occludin and tricellulin under support of ZO-1. Quantitatively, the sealing capacity is mainly accomplished by two cell (-like) TJs. The barrier function is subject of versatile regulation by signalling pathways relevant under normal and pathological conditions that particularly target claudin-5 and, to an even greater extent, occludin.

4. Tight Junctions and Pathologies of the Brain

In Table 4, disease states and diseases are compiled, which are accompanied by BBB impairment and TJ protein involvement. It is a widely held consideration that BBB damage is a consequence of many severe pathological processes of the brain. However, evidence is given that barrier disturbances can also be triggered by peripheral diseases [313] or by mutations of TJ proteins [115,314]. Leakage of the barrier is observed in the early stages of some brain diseases and might even contribute to disease progression [315,316]. Various cerebral diseases, such as ischemia and related disorders, tumours or, inflammatory processes, can lead to BBB disturbances, imbalances of ion-/molecular fluxes, increased extravasation of blood cells, and impaired TJ morphology [317]. Novel BBB models of human-induced pluripotent stem cells have been introduced to study diverse neurological diseases [318]. Details are given in Table 4.

Similar alterations of the barrier are described for neurodegenerative [359] and psychiatric disorders (e.g., schizophrenia, autism spectrum disorder, affective disorders) [330]. In the context of Alzheimer’s disease, angiogenic processes can be triggered by β-amyloid, which result in a loss of microvascular TJ proteins (claudin-1, -5) and increased permeability of the barrier in rodent brain [319,320]. In human stem cell models, claudin-3 and -5 are found up-regulated [321]. In patients with Alzheimer’s disease, plasma claudin-5 levels are increased; the protein has been suggested as a potential biomarker for the diagnosis of AD [360].

Multiple sclerosis is characterised by decreased levels of claudin-11 at the BBB of patients [130] and of claudin-3 in a mouse model which exhibits lowered barrier tightness [78]. Another mouse study revealed down-regulation of angulin-1, suggesting that tricellular TJs could be disturbed during multiple sclerosis [228]. The inflammatory cytokine IFNγ safeguards tight junctions of the BBB in a mouse model of multiple sclerosis by up-regulating claudin-5, which could be inhibited by TNFα and IL17 [361], revealing a physiological protective mechanism of the BBB during inflammation.

In a model of amyotrophic lateral sclerosis, reduction of claudin-5, occludin, and ZO-1 in endothelial cells results in microhaemorrhages before motor neuron degeneration and neurovascular inflammatory markers occur, indicating a central contribution to disease initiation [324]. For schizophrenia, a variant in the claudin-5 gene is reported, leading to suppression of claudin-5 [314]. Interestingly, loss of TJ proteins from a damaged BBB can be detected in the peripheral blood of autistic children (claudin-5, -11, occludin) [126], supporting earlier findings that claudin-5 is released from the brain endothelium during disease. Claudin-5 can be transferred to circulating leukocytes, which could support leukocyte transendothelial migration into the CNS [116].

The BBB in brain tumours is widely intact in early stages but breaks down during progression of the tumour [331] with a concomitant diminution of claudin-1, -3, -5, and occludin [78,80,93]. Many different types of brain tumours have been documented, showing large heterogeneity. They arise from primary tumours, such as glioblastoma or astrocytoma, and metastatic tumours frequently originate from breast or lung cancer [362].

Breakdown of the BBB is well documented for ischemic states [9,338], which lead to disorders such as stroke or oedema [363]. At the molecular level, multiple factors are discussed: oxidative/nitrosative stress, metabolic/ionic dysregulation, and/or inflammatory/neurodegenerative processes [364]. Experimental ischemia/reperfusion results in the loss of claudin-1, -3, -12, and occludin, whereas claudin-5 has been found to be up-regulated 3 h after occlusion [50,53]. After 120 h, similar effects have been observed for occludin and ZO-1, but this was also true for claudin-5 in the study in question, suggesting a biphasic time-course [338]. Claudin-5 has been also found in the serum of stroke patients [127]. Studies on protective approaches often report claudin-5 preservation, e.g., by a novel antioxidant, attenuating BBB breakdown via erythroid 2-like 2 nuclear translocation/haem oxygenase 1 signalling stimulation [129], by small molecules [365], or by mesenchymal stem cells [366]. Endothelial reduction of claudin-25 and the subsequent permeability increase for small molecules have been shown for cerebellar haemorrhage [76]. Disturbances of the cerebral circulation are fostered by obesity [345], diabetes mellitus [340], or microangiopathies [342]. BBB leakage is also accompanied by the down-regulation of claudin-12, occludin, and ZO-1 in obesity with concomitant type II diabetes [141], or of claudin-5 and occludin in diabetes [341]. Interestingly, Tie2+ macrophages promote endogenous revascularisation in mouse brains after ischemic injury [367], which possibly leads to reconstruction of the BBB.

Infarct progression and oedema formation can be increased by a tight barrier [53]. Absence of claudin-3 and a reduced level of occludin can limit the infarcted and oedematous area. Consequently, TJ modulation has been postulated as an approach to treating stroke and related disorders at least early after onset. There is good evidence that mild trauma resulting in BBB disruption in rats opens a paracellular pathway of approximately 22 nm, consistent with disrupted TJs, leaving adherens junctions intact [368]. In this context, EphA4/Tie2/Akap12 signalling has been reported to limit the expression of claudin-5 and to mediate microvascular dysfunction [128]. On the other hand, trauma-associated brain oedema can be diminished via suppression of claudin-5 after administration of the corresponding siRNA in rats [335] or by a novel inhibitor of claudin-5 interactions [369], which also alleviates ZO-1 degradation [336]. In addition to its direct effect, claudin-5 siRNA can be applied to improve the pharmacokinetics of agents targeting brain diseases [185]. There are other modulators discussed in this context: claudin-5 shRNA [370], monoclonal anti-claudin antibodies [371], and peptides (disclosed by phage display [372,373,374] or derived from sequences of the extracellular loop 1 of claudins [190,199]), which exerted transient BBB opening. The last-mentioned approaches can be generalised to the extent that small agents can be developed according to this principle to open the BBB transiently and size-selectively and provide conditions allowing for the delivery of a wide range of compounds for the treatment of neurodegenerative, neuropsychiatric, and malignant diseases. For the delivery of larger molecules, such as antisense oligonucleotides, the angulin-1 binder angubindin-1 has been applied in vivo. The data demonstrate that not only bicellular but also tricellular TJs may be targeted to improve drug permeation through the BBB [375].

Cerebral inflammation is often induced by infections. Zika or meningitis viruses cause disruption of the mouse BBB and down-regulation of claudin-5 [350,354]. The malaria pathogen Plasmodium falciparum elicits vascular permeability, fatal brain oedema, and down-regulation of claudin-5 and occludin [353]. Chronic inflammatory pain induced by peripheral injection of complete Freund’s adjuvant suppressed occludin but up-regulated claudin-3 and -5 with simultaneous opening of the barrier [182]. Various mediators and pathways are involved in alterations of TJ proteins during inflammation. Vascular endothelial growth factor contributes to BBB opening [83,346] by down-regulating claudin-5 [332]. Increased permeability is also caused by pro-inflammatory stimuli such as thrombin [239] or microbial toxins down-regulating occludin and claudin-5 [347]. Barrier strengthening can be achieved via the administration of anti-inflammatory agents, e.g., of angiopoietin-1, which promotes occludin-ZO-1 interaction and stabilises TJs by inhibiting thrombin-induced Tyr-phosphorylation of occludin [239].

Reviewing the latest experimental data and the increasing number of clinical studies reveals more and more neurological disorders characterised by BBB involvement. In the vast majority of cases, disturbances of the TJs at the molecular level of claudin-5 are involved, with evidence of pathogenic significance. Modulation of three cellular TJ-proteins provides a novel approach for drug delivery. Human-induced stem cell models offer diagnostic potential in analysing various neurological diseases individually. These advances have led to new diagnostic approaches and will further encourage pharmacological studies.

5. Conclusions and Perspectives

Tight junctions are of crucial importance for the BBB, which both directly and indirectly controls the overwhelming majority of the exchange mechanisms between the brain and blood. On the other hand, a functional barrier may also cause problems such as reduced edema drainage in stroke or trauma or insufficient drug delivery to tumours. Further progress in understanding the BBB requires reliable BBB models; previous model investigations often applied non-human cells with dedifferentiated TJ proteins. Recent developments favour models using human primary and induced pluripotent stem cells. For in vivo studies, the prospects of genetically modified mice should be further exploited in the context of TJs. These approaches bear great potential for BBB-related research with high clinical relevance.

Elucidation of the molecular composition of TJs revealed that claudin-5 plays a central role in tightening the BBB, but the TJ does not solely depend on this claudin; it must be considered in concert with other TJ proteins. In particular, the impact of claudin-11 and tricellulin/angulin requires further experimental and clinical studies. Numerous signalling pathways relevant to the BBB have been clarified, and above all, we have described the role of these in pathologies, as is increasingly being shown clinically. Claudin-5 can be regulated directly, but more often, indirect regulation via occludin is observed. More insight into these processes will open up new diagnostic and therapeutic perspectives.

Nevertheless, the exact role that the BBB plays is still unclear in many CNS diseases, especially the extent to which it itself can cause cerebral dysfunction. Generally, its opening is considered to be a consequence of disease progression, but there is evidence that the BBB disruption is pathogenetic early in the development of disorders. We confidently expect that further molecular mechanisms and protein structures will be disclosed to advance our understanding of TJ biology and to be translated into new therapeutic approaches.

Acknowledgments

The support of the Henan China-Germany International Joint Laboratory for promotion of the international collaboration is gratefully acknowledged. The authors thank Chen Ni for his help in literature searching, writing and figure drawing.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/ijms25115601/s1.

Conflicts of Interest

The authors declare no conflicts of interest.

Figure 1 The blood-brain barrier (BBB). (A) The BBB is formed by capillary endothelial cells (EC) under the influence of other neurovascular components, such as astrocyte endfeet (AC) and pericytes (PC). (B) Tight junctions (TJs) seal the gap between ECs. AJ, adherens junction [9]. (C) Routes of passage at the BBB. TJs virtually prevent paracellular diffusion (red) and mandate transcellular transport (plasma membrane/cytosol, purple), active/facilitated transport (transporters/membrane channels, black), receptor-mediated transcytosis (green), or activation of efflux transporters (orange).

Figure 2 Scheme of tight junctions (TJs). (A) Longitudinal and circular TJ areas at the most luminal part of the lateral plasma membrane of brain capillary endothelial cells (EC). (B) Paracellular sealing by transmembrane TJ proteins forming a belt-like strand network of neighbouring plasma membranes. (C) Tricellular TJs as formed by non-endothelial cells (bicellular TJ, bTJ; tricellular TJ, tTJ). (D) Protein interactions at the TJs: claudins, occludin, JAMs, and tricellulin oligomerise along the plasma membrane and between two and/or three cell (-like) membranes. These proteins are recruited by the scaffolding protein ZO-1. Self-association occurs extracellularly (claudins), N-terminally (JAMs), C-terminally (occludin), or via PDZ2 domain (ZO-1). C-termini bind to PDZ1 (claudins), PDZ3 (JAMs), or to the SH3-Hinge-GuK unit (occludin) of ZO-1. The SH3-Hinge-GuK unit of ZO-1 also interacts with regulatory molecules, such as guanine nucleotide-binding protein G(i) subunit alpha-2 (Gαi2) or Y-box transcription factor ZONAB (ZO-1-associated nucleic acid binding protein).

Figure 5 mRNA expression of tight junction (TJ) proteins in human and mouse brain endothelium. Proportions of individual proteins of the total expression of TJ protein mRNA. High abundance, >1%; low abundance, <1% of total mRNA ([50], modified). Cldn, claudin; Ocln, occludin; Tric, tricellulin.

ijms-25-05601-t004_Table 4 Table 4 Pathologies, alterations of permeability and of tight junction proteins at the blood-brain barrier.

Type of Disorder	Leakage of Blood-Brain Barrier	Tight Junction Alteration	
neurodegeneration	- m. Alzheimer mouse model [319,320]; iBEC layer, mutant transfected [321]	- ß-amyloid triggered angiogenesis
→ Cldn1, -5 down-regulated [319,320]
→ Cldn3, -5 up-regulated [321]	
	- multiple sclerosis [322]

- EAE [228]	→ down-regulated: Cldn3 (EAE) [78], Cldn11 (patient, EAE/mouse) [130]

→ angulin-1 down, 3-cell contacts [228]	
	- amyotrophic lateral sclerosis [323]	- mouse model → BCSFB: loss of Cldn5, Ocln, ZO-1 [324]	
	- m. Parkinson, extravasation in
striatum [325]	- rat model → Cldn5, Ocln, ZO-1 up-regulated (substantia nigra) [326]	
	- chorea Huntington, human and mouse model [327,328]	→ Occl, ZO-1 reduced in iBEC [328]	
epilepsy	- cainic acid-induced seizures, temporal lope epilepsy [329]	- resected brain → Cldn5, Ocln, ZO-1 reduced [329]	
psychiatric
disorders	- schizophrenia, autism spectrum disorder (ADS), affective disorders [330]
- ADS, cortex	→ Cldn12, Ocln, ZO-1 down-regulated [330]

→ Cldn3, -5, -12, Tric up [271]	
	- schizophrenia associated with Cldn5 gene variant [314]	→ lessens Cldn5 in BEC; antipsychotic drug enhances Cldn5 [314]	
brain tumours	- advanced tumour grades [78,93,331]	→ reduction of Cldn1, -3, -5, Ocln
(glioblastoma) [78,80,332]	
traumatic
brain injury	- rat model [333]
- patients [334]
- Cldn5-si/shRNA enhanced leakage, reduced swelling [335]	→Ocln, ZO-1 reduced [333]

→ Cldn5 reversibly down-regulated [335]
→ ZO-1 degradation [336]	
ischemia/stroke	- acute ischemic stroke, human [337]
- ischemia/reperfusion, mouse [129]	- at clinical worsening → Cldn5, Cldn5:ZO-1 ratio increased in blood [127]	
	- middle cerebral artery occlusion [228,338]	→ 3 h: Cldn1, -3, -12, Ocln dropped, but Cldn5 rose [50,53]; 5 d: Cldn5, Ocln, ZO-1 reduced [338]
→ angulin-1 down, 3-cell contact [228]	
	- hypoxia/glucose lack, BEC [200]	→ Cldn5, Ocln, ZO-1 down [339]	
	- haemorrhage [76,104]	→ Cldn25 down-regulated (BEC) [76]
→ Cldn3, -5 down; improvement/reduced leak by anti-malaria drug [104]	
- reinforced by	- d. mellitus [340]
- BRB leakage in murine diabetic retinopathy [341]
- microangiopathy: small vessel disease, stroke imaging [342]; iBEC layer, mutant transfected [343]	
→ Cldn5, Ocln depressed [341]

→ Cldn5 and ZO-1 expression reduced (autopsy samples) [344]
→ Cldn5-, Ocln-junctions affected [343]	
high-fat diet	- diet-induced obese diabetic mice [141]; obesity [345]	→ Cldn12, Ocln, ZO-1 reduced [141]	
inflammation	- thrombin-caused, BEC layer [239]
- astrocyte-derived VEGF [346]	→ Ocln-ZO-1 binding lost [239]
→ Cldn5 decrease in BEC [332]	
	- peripheral (CFA) [182,347,348]
- pancreatitis [349]	→ Ocln down/Cldn3, -5 up (CFA) [182]
→ degradation of ZO-1, Cldn5 [349]	
infection	- Zika virus in mice [350]	→ Cldn5 down [350], via miR-101-3p [351]	
	- bacterial pertussis toxin [347]	→ ZO-1 down (BCSFB) [352]	
	- Plasmodium falciparum [353]
- Neisseria meningitidis, iBEC [354]
- long COVID patients [355]	→ Cldn5, Ocln down (mouse) [353]
→ Cldn5, Ocln down (cell layer) [354]
→ Cldn5 down (mouse) [356]	
hypertonia	- acute in rat [357]	→ Cldn3, -5, -12 depression [357]	
alcohol abuse	- hippocampal IgG extravasation [358]	→ Cldn5 down [358]	
microcephaly	- small molecule flux higher [115]	→ human Cldn5-G60R (ECL1) [115]	
BCSFB, blood-cerebrospinal fluid barrier; BEC, brain endothelial cells; BRB, blood-retina barrier; CFA, complete Freund’s adjuvant; Cldn, claudin; EAE, experimental autoimmune encephalitis; ECL, extracellular loop; iBEC, BEC induced from human embryonic stem cells; Ocln, occludin; VEGF, vascular endothelial growth factor; ZO-1, zonula occludens protein 1.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
==== Refs
References

1. Rodriguez-Boulan E. Macara I.G. Organization and execution of the epithelial polarity programme Nat. Rev. Mol. Cell Biol. 2014 15 225 242 10.1038/nrm3775 24651541
2. Farquhar M.G. Palade G.E. Junctional Complexes in Various Epithelia J. Cell Biol. 1963 17 375 412 10.1083/jcb.17.2.375 13944428
3. Irie K. Shimizu K. Sakisaka T. Ikeda W. Takai Y. Roles and modes of action of nectins in cell-cell adhesion Semin. Cell Dev. Biol. 2004 15 643 656 10.1016/S1084-9521(04)00088-6 15561584
4. Hartsock A. Nelson W.J. Adherens and tight junctions: Structure, function and connections to the actin cytoskeleton Biochim. Biophys. Acta Biomembr. 2008 1778 660 669 10.1016/j.bbamem.2007.07.012 17854762
5. Baum B. Georgiou M. Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling J. Cell Biol. 2011 192 907 917 10.1083/jcb.201009141 21422226
6. Schulze C. Firth J.A. Immunohistochemical localization of adherens junction components in blood-brain-barrier microvessels of the rat J. Cell Sci. 1993 104 773 782 10.1242/jcs.104.3.773 8314872
7. Rouaud F. Sluysmans S. Flinois A. Shah J. Vasileva E. Citi S. Scaffolding proteins of vertebrate apical junctions: Structure, functions and biophysics Biochim. Biophys. Acta Biomembr. 2020 1862 183399 10.1016/j.bbamem.2020.183399 32553946
8. Nagasawa K. Chiba H. Fujita H. Kojima T. Saito T. Endo T. Sawada N. Possible involvement of gap junctions in the barrier function of tight junctions of brain and lung endothelial cells J. Cell. Physiol. 2006 208 123 132 10.1002/jcp.20647 16547974
9. Weiss N. Miller F. Cazaubon S. Couraud P.O. The blood-brain barrier in brain homeostasis and neurological diseases Biochim. Biophys. Acta Biomembr. 2009 1788 842 857 10.1016/j.bbamem.2008.10.022 19061857
10. Staehelin L.A. Further observations on fine-structure of freeze-cleaved tight junctions J. Cell Sci. 1973 13 763 786 10.1242/jcs.13.3.763 4203962
11. Shen L. Weber C.R. Raleigh D.R. Yu D. Tumer J.R. Tight, Junction Pore and Leak Pathways: A Dynamic Duo Annual Review of Physiology Julius D. Clapham D.E. Annual Reviews San Mateo, CA, USA 2011 Volume 73 283 309
12. Kirschner N. Rosenthal R. Furuse M. Moll I. Fromm M. Brandner J.M. Contribution of Tight Junction Proteins to Ion, Macromolecule, and Water Barrier in Keratinocytes J. Investig. Dermatol. 2013 133 1161 1169 10.1038/jid.2012.507 23407391
13. Krause G. Winkler L. Mueller S.L. Haseloff R.F. Piontek J. Blasig I.E. Structure and function of claudins Biochim. Biophys. Acta Biomembr. 2008 1778 631 645 10.1016/j.bbamem.2007.10.018 18036336
14. Anderson J.M. Van Itallie C.M. Physiology and Function of the Tight Junction Cold Spring Harbor Perspect. Biol. 2009 1 a002584 10.1101/cshperspect.a002584 20066090
15. Kooij G. Kopplin K. Blasig R. Stuiver M. Koning N. Goverse G. van der Pol S.M.A. Hof B.V. Gollasch M. Drexhage J.A.R. Disturbed function of the blood-cerebrospinal fluid barrier aggravates neuro-inflammation Acta Neuropathol. 2014 128 267 277 10.1007/s00401-013-1227-1 24356983
16. Gonzalez-Mariscal L. Namorado M.C. Martin D. Luna J. Alarcon L. Islas S. Valencia L. Muriel P. Ponce L. Reyes J.L. Tight junction proteins ZO-1, ZO-2, and occludin along isolated renal tubules Kidney Int. 2000 57 2386 2402 10.1046/j.1523-1755.2000.00098.x 10844608
17. Cao X.W. Surma M.A. Simons K. Polarized sorting and trafficking in epithelial cells Cell Res. 2012 22 793 805 10.1038/cr.2012.64 22525333
18. Cereijido M. Valdes J. Shoshani L. Contreras R.G. Role of tight junctions in establishing and maintaining cell polarity Annu. Rev. Physiol. 1998 60 161 177 10.1146/annurev.physiol.60.1.161 9558459
19. Matter K. Aijaz S. Tsapara A. Balda M.S. Mammalian tight junctions in the regulation of epithelial differentiation and proliferation Curr. Opin. Cell Biol. 2005 17 453 458 10.1016/j.ceb.2005.08.003 16098725
20. Furuse M. Fujita K. Hiiragi T. Fujimoto K. Tsukita S. Claudin-1 and -2: Novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin J. Cell Biol. 1998 141 1539 1550 10.1083/jcb.141.7.1539 9647647
21. Morita K. Furuse M. Fujimoto K. Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands Proc. Natl. Acad. Sci. USA 1999 96 511 516 10.1073/pnas.96.2.511 9892664
22. Raleigh D.R. Marchiando A.M. Zhang Y. Shen L. Sasaki H. Wang Y.M. Long M.Y. Turner J.R. Tight Junction-associated MARVEL Proteins MarvelD3, Tricellulin, and Occludin Have Distinct but Overlapping Functions Mol. Biol. Cell 2010 21 1200 1213 10.1091/mbc.e09-08-0734 20164257
23. Martin-Padura I. Lostaglio S. Schneemann M. Williams L. Romano M. Fruscella P. Panzeri C. Stoppacciaro A. Ruco L. Villa A. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration J. Cell Biol. 1998 142 117 127 10.1083/jcb.142.1.117 9660867
24. Guillemot L. Paschoud S. Pulimeno P. Foglia A. Citi S. The cytoplasmic plaque of tight junctions: A scaffolding and signalling center Biochim. Biophys. Acta Biomembr. 2008 1778 601 613 10.1016/j.bbamem.2007.09.032 18339298
25. Ivanov A.I. Nusrat A. Parkos C.A. Endocytosis of epithelial apical junctional proteins by a clathrin-mediated pathway into a unique storage compartment Mol. Biol. Cell 2004 15 176 188 10.1091/mbc.e03-05-0319 14528017
26. Zwanziger D. Staat C. Andjelkovic A.V. Blasig I.E. Claudin-derived peptides are internalized via specific endocytosis pathways Barriers and Channels Formed by Tight Junction Proteins I Fromm M. Schulzke J.D. Wiley Online Library Hoboken, NJ, USA 2012 Volume 1257 29 37
27. Stamatovic S.M. Keep R.F. Wang M.M. Jankovic I. Andjelkovic A.V. Caveolae-mediated Internalization of Occludin and Claudin-5 during CCL2-induced Tight Junction Remodeling in Brain Endothelial Cells J. Biol. Chem. 2009 284 19053 19066 10.1074/jbc.M109.000521 19423710
28. Bruewer M. Utech M. Ivanov A.I. Hopkins A.M. Parkos C.A. Nusrat A. Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process FASEB J. 2005 19 923 933 10.1096/fj.04-3260com 15923402
29. Takahashi S. Iwamoto N. Sasaki H. Ohashi M. Oda Y. Tsukita S. Furuse M. The E3 ubiquitin ligase LNX1p80 promotes the removal of claudins from tight junctions in MDCK cells J. Cell Sci. 2009 122 985 994 10.1242/jcs.040055 19295125
30. Gehne N. Lamik A. Lehmann M. Haseloff R.F. Andjelkovic A.V. Blasig I.E. Cross-over endocytosis of claudins is mediated by interactions via their extracellular loops PLoS ONE 2017 12 e0182106 10.1371/journal.pone.0182106 28813441
31. Mineta K. Yamamoto Y. Yamazaki Y. Tanaka H. Tada Y. Saito K. Tamura A. Igarashi M. Endo T. Takeuchi K. Predicted expansion of the claudin multigene family FEBS Lett. 2011 585 606 612 10.1016/j.febslet.2011.01.028 21276448
32. Furuse M. Tsukita S. Claudins in occluding junctions of humans and flies Trends Cell Biol. 2006 16 181 188 10.1016/j.tcb.2006.02.006 16537104
33. Suzuki H. Nishizawa T. Tani K. Yamazaki Y. Tamura A. Ishitani R. Dohmae N. Tsukita S. Nureki O. Fujiyoshi Y. Crystal Structure of a Claudin Provides Insight into the Architecture of Tight Junctions Science 2014 344 304 307 10.1126/science.1248571 24744376
34. Saitoh Y. Suzuki H. Tani K. Nishikawa K. Irie K. Ogura Y. Tamura A. Tsukita S. Fujiyoshi Y. Structural insight into tight junction disassembly by Clostridium perfringens enterotoxin Science 2015 347 775 778 10.1126/science.1261833 25678664
35. Shinoda T. Shinya N. Ito K. Ohsawa N. Terada T. Hirata K. Kawano Y. Yamamoto M. Kimura-Someya T. Yokoyama S. Structural basis for disruption of claudin assembly in tight junctions by an enterotoxin Sci. Rep. 2016 6 33632 10.1038/srep33632 27647526
36. Vecchio A.J. Stroud R.M. Claudin-9 structures reveal mechanism for toxin-induced gut barrier breakdown Proc. Natl. Acad. Sci. USA 2019 116 17817 17824 10.1073/pnas.1908929116 31434788
37. Gunzel D. Yu A.S.L. Claudins and the modulation of tight junction permeability Physiol. Rev. 2013 93 525 569 10.1152/physrev.00019.2012 23589827
38. Tsukita S. Tanaka H. Tamura A. The Claudins: From Tight Junctions to Biological Systems Trends Biochem. Sci. 2019 44 141 152 10.1016/j.tibs.2018.09.008 30665499
39. Zhang Y.N. Yeh S. Appleton B.A. Held H.A. Kausalya P.J. Phua D.C.Y. Wong W.L. Lasky L.A. Wiesmann C. Hunziker W. Convergent and divergent ligand specificity among PDZ domains of the LAP and zonula occludens (ZO) families J. Biol. Chem. 2006 281 22299 22311 10.1074/jbc.M602902200 16737968
40. Itoh M. Furuse M. Morita K. Kubota K. Saitou M. Tsukita S. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2 and ZO-3, with the COOH termini of claudins J. Cell Biol. 1999 147 1351 1363 10.1083/jcb.147.6.1351 10601346
41. Ruffer C. Gerke V. The C-terminal cytoplasmic tail of claudins 1 and 5 but not its PDZ-binding motif is required for apical localization at epithelial and endothelial tight junctions Eur. J. Cell Biol. 2004 83 135 144 10.1078/0171-9335-00366 15260435
42. Liu J. Weaver J. Jin X.C. Zhang Y. Xu J. Liu K.J. Li W.P. Liu W.L. Nitric Oxide Interacts with Caveolin-1 to Facilitate Autophagy-Lysosome-Mediated Claudin-5 Degradation in Oxygen-Glucose Deprivation-Treated Endothelial Cells Mol. Neurobiol. 2016 53 5935 5947 10.1007/s12035-015-9504-8 26515186
43. Tanaka M. Kamata R. Sakai R. EphA2 phosphorylates the cytoplasmic tail of claudin-4 and mediates paracellular permeability J. Biol. Chem. 2005 280 42375 42382 10.1074/jbc.M503786200 16236711
44. Van Itallie C.M. Gambling T.M. Carson J.L. Anderson J.M. Palmitoylation of claudins is required for efficient tight-junction localization J. Cell Sci. 2005 118 1427 1436 10.1242/jcs.01735 15769849
45. Lohrberg D. Krause E. Schumann M. Piontek J. Winkler L. Blasig I.E. Haseloff R.F. A strategy for enrichment of claudins based on their affinity to Clostridium perfringens enterotoxin BMC Mol. Biol. 2009 10 61 10.1186/1471-2199-10-61 19545418
46. Gow A. Southwood C.M. Li J.S. Pariali M. Riordan G.P. Brodie S.E. Danias J. Bronstein J.M. Kachar B. Lazzarini R.A. CNS myelin and Sertoli cell tight junction strands are absent in Osp/Claudin-11 null mice Cell 1999 99 649 659 10.1016/S0092-8674(00)81553-6 10612400
47. Gow A. Davies C. Southwood C.M. Frolenkov G. Chrustowski M. Ng L. Yamauchi D. Marcus D.C. Kachar B. Deafness in Claudin 11-null mice reveals the critical contribution of basal cell tight junctions to stria vascularis function J. Neurosci. 2004 24 7051 7062 10.1523/JNEUROSCI.1640-04.2004 15306639
48. Gupta I.R. Ryan A.K. Claudins: Unlocking the code to tight junction function during embryogenesis and in disease Clin. Genet. 2010 77 314 325 10.1111/j.1399-0004.2010.01397.x 20447145
49. Haseloff R.F. Dithmer S. Winkler L. Wolburg H. Blasig I.E. Transmembrane proteins of the tight junctions at the blood-brain barrier: Structural and functional aspects Semin. Cell Dev. Biol. 2015 38 16 25 10.1016/j.semcdb.2014.11.004 25433243
50. Berndt P. Winkler L. Cording J. Breitkreuz-Korff O. Rex A. Dithmer S. Rausch V. Blasig R. Richter M. Sporbert A. Tight junction proteins at the blood-brain barrier: Far more than claudin-5 Cell. Mol. Life Sci. 2019 76 1987 2002 10.1007/s00018-019-03030-7 30734065
51. Gregory M. Dufresne J. Hermo L. Cyr D.G. Claudin-1 is not restricted to tight junctions in the rat epididymis Endocrinology 2001 142 854 863 10.1210/endo.142.2.7975 11159859
52. Inai T. Sengoku A. Hirose E. Iida H. Shibata Y. Claudin-7 expressed on lateral membrane of rat epididymal epithelium does not form aberrant tight junction strands Anat. Rec. Adv. Integr. Anat. Evol. Biol. 2007 290 1431 1438 10.1002/ar.20597
53. Winkler L. Blasig R. Breitkreuz-Korff O. Berndt P. Dithmer S. Helms H.C. Puchkov D. Devraj K. Kaya M. Qin Z. Tight junctions in the blood-brain barrier promote edema formation and infarct size in stroke—Ambivalent effects of sealing proteins J. Cereb. Blood Flow Metab. 2020 41 132 145 10.1177/0271678X20904687 32054373
54. Piontek J. Winkler L. Wolburg H. Müller S.L. Zuleger N. Piehl C. Wiesner B. Krause G. Blasig I.E. Formation of tight junction: Determinants of homophilic interaction between classical claudins Faseb J. 2008 22 146 158 10.1096/fj.07-8319com 17761522
55. Cording J. Berg J. Kading N. Bellmann C. Tscheik C. Westphal J.K. Milatz S. Gunzel D. Wolburg H. Piontek J. In tight junctions, claudins regulate the interactions between occludin, tricellulin and marvelD3, which, inversely, modulate claudin oligomerization J. Cell Sci. 2013 126 554 564 10.1242/jcs.114306 23203797
56. Inai T. Kobayashi J. Shibata Y. Claudin-1 contributes to the epithelial barrier function in MDCK cells Eur. J. Cell Biol. 1999 78 849 855 10.1016/S0171-9335(99)80086-7 10669103
57. Furuse M. Furuse K. Sasaki H. Tsukita S. Conversion of Zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells J. Cell Biol. 2001 153 263 272 10.1083/jcb.153.2.263 11309408
58. Amasheh S. Meiri N. Gitter A.H. Schoneberg T. Mankertz J. Schulzke J.D. Fromm M. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells J. Cell Sci. 2002 115 4969 4976 10.1242/jcs.00165 12432083
59. Milatz S. Krug S.M. Rosenthal R. Gunzel D. Muller D. Schulzke J.D. Amasheh S. Fromm M. Claudin-3 acts as a sealing component of the tight junction for ions of either charge and uncharged solutes Biochim. Biophys. Acta Biomembr. 2010 1798 2048 2057 10.1016/j.bbamem.2010.07.014 20655293
60. Van Itallie C. Rahner C. Anderson J.M. Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability J. Clin. Investig. 2001 107 1319 1327 10.1172/JCI12464 11375422
61. Hou J.H. Renigunta A. Yang J. Waldegger S. Claudin-4 forms paracellular chloride channel in the kidney and requires claudin-8 for tight junction localization Proc. Natl. Acad. Sci. USA 2010 107 18010 18015 10.1073/pnas.1009399107 20921420
62. Colegio O.R. Van Itallie C.M. McCrea H.J. Rahner C. Anderson J.M. Claudins create charge-selective channels in the paracellular pathway between epithelial cells Am. J. Physiol. Cell Physiol. 2002 283 C142 C147 10.1152/ajpcell.00038.2002 12055082
63. Nitta T. Hata M. Gotoh S. Seo Y. Sasaki H. Hashimoto N. Furuse M. Tsukita S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice J. Cell Biol. 2003 161 653 660 10.1083/jcb.200302070 12743111
64. Hou J.H. Gomes A.S. Paul D.L. Goodenough D.A. Study of claudin function by RNA interference J. Biol. Chem. 2006 281 36117 36123 10.1074/jbc.M608853200 17018523
65. Alexandre M.D. Lu Q. Chen Y.H. Overexpression of claudin-7 decreases the paracellular Cl- conductance and increases the paracellular Na+ conductance in LLC-PK1 cells J. Cell Sci. 2005 118 2683 2693 10.1242/jcs.02406 15928046
66. Sas D. Hu M.C. Moe O.W. Baum M. Effect of claudins 6 and 9 on paracellular permeability in MDCK II cells Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008 295 R1713 R1719 10.1152/ajpregu.90596.2008 18784328
67. Van Itallie C.M. Rogan S. Yu A. Vidal L.S. Holmes J. Anderson J.M. Two splice variants of claudin-10 in the kidney create paracellular pores with different ion selectivities Am. J. Physiol. Renal Physiol. 2006 291 F1288 F1299 10.1152/ajprenal.00138.2006 16804102
68. Abuazza G. Becker A. Williams S.S. Chakravarty S. Truong H.T. Lin F.M. Baum M. Claudins 6, 9, and 13 are developmentally expressed renal tight junction proteins Am. J. Physiol. Renal Physiol. 2006 291 F1132 F1141 10.1152/ajprenal.00063.2006 16774906
69. Yu A.S.L. Enck A.H. Lencer W.I. Schneeberger E.E. Claudin-8 expression in Madin-Darby canine kidney cells augments the paracellular barrier to cation permeation J. Biol. Chem. 2003 278 17350 17359 10.1074/jbc.M213286200 12615928
70. Krug S.M. Gunzel D. Conrad M.P. Rosenthal R. Fromm A. Amasheh S. Schulzke J.D. Fromm M. Claudin-17 forms tight junction channels with distinct anion selectivity Cell. Mol. Life Sci. 2012 69 2765 2778 10.1007/s00018-012-0949-x 22402829
71. Ben-Yosef T. Belyantseva I.A. Saunders T.L. Hughes E.D. Kawamoto K. Van Itallie C.M. Beyer L.A. Halsey K. Gardner D.J. Wilcox E.R. Claudin 14 knockout mice, a model for autosomal recessive deafness DFNB29, are deaf due to cochlear hair cell degeneration Hum. Mol. Genet. 2003 12 2049 2061 10.1093/hmg/ddg210 12913076
72. Hou J.H. Renigunta A. Konrad M. Gornes A.S. Schneeberger E.E. Paul D.L. Waldegger S. Goodenough D.A. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex J. Clin. Investig. 2008 118 619 628 10.1172/JCI33970 18188451
73. McCabe M.J. Foo C.F.H. Dinger M.E. Smooker P.M. Stanton P.G. Claudin-11 and occludin are major contributors to Sertoli cell tight junction function, in vitro Asian J. Androl. 2016 18 620 626 26585695
74. Jovov B. Van Itallie C.M. Shaheen N.J. Carson J.L. Gambling T.M. Anderson J.M. Orlando R.C. Claudin-18: A dominant tight junction protein in Barrett’s esophagus and likely contributor to its acid resistance Am. J. Physiol. Gastroint. Liver Physiol. 2007 293 G1106 G1113 10.1152/ajpgi.00158.2007 17932229
75. Tanaka H. Yamamoto Y. Kashihara H. Yamazaki Y. Tani K. Fujiyoshi Y. Mineta K. Takeuchi K. Tamura A. Tsukita S. Claudin-21 Has a Paracellular Channel Role at Tight Junctions Mol. Cell. Biol. 2016 36 954 964 10.1128/MCB.00758-15 26729464
76. Ohnishi M. Ochiai H. Matsuoka K. Akagi M. Nakayama Y. Shima A. Uda A. Matsuoka H. Kamishikiryo J. Michihara A. Claudin Domain Containing 1 Contributing to Endothelial Cell Adhesion Decreases in Presence of Cerebellar Hemorrhage J. Neurosci. Res. 2017 95 2051 2058 10.1002/jnr.24040 28244141
77. Mahajan S.D. Aalinkeel R. Sykes D.E. Reynolds J.L. Bindukumar B. Adal A. Qi M. Toh J. Xu G. Prasad P.N. Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse Brain Res. 2008 1203 133 148 10.1016/j.brainres.2008.01.093 18329007
78. Wolburg H. Wolburg-Buchholz K. Kraus J. Rascher-Eggstein G. Liebner S. Hamm S. Duffner F. Grote E.H. Risau W. Engelhardt B. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme Acta Neuropathol. 2003 105 586 592 10.1007/s00401-003-0688-z 12734665
79. Hanske S. Dyrna F. Bechmann I. Krueger M. Different segments of the cerebral vasculature reveal specific endothelial specifications, while tight junction proteins appear equally distributed Brain Struct. Funct. 2017 222 1179 1192 10.1007/s00429-016-1267-0 27435201
80. Liebner S. Fischmann A. Rascher G. Duffner F. Grote E.H. Kalbacher H. Wolburg H. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme Acta Neuropathol. 2000 100 323 331 10.1007/s004010000180 10965803
81. Furuse M. Hata M. Furuse K. Yoshida Y. Haratake A. Sugitani Y. Noda T. Kubo A. Tsukita S. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: A lesson from claudin-1-deficient mice J. Cell Biol. 2002 156 1099 1111 10.1083/jcb.200110122 11889141
82. McCarthy K.M. Francis S.A. McCormack J.M. Lai J. Rogers R.A. Skare I.B. Lynch R.D. Schneeberger E.E. Inducible expression of claudin-1-myc but not occludin-VSV-G results in aberrant tight junction strand formation in MDCK cells J. Cell Sci. 2000 113 3387 3398 10.1242/jcs.113.19.3387 10984430
83. Pfeiffer F. Schafer J. Lyck R. Makrides V. Brunner S. Schaeren-Wiemers N. Deutsch U. Engelhardt B. Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis Acta Neuropathol. 2011 122 601 614 10.1007/s00401-011-0883-2 21983942
84. Mailly L. Baumert T.F. Hepatitis C virus infection and tight junction proteins: The ties that bind Biochim. Biophys. Acta Biomembr. 2020 1862 183296 10.1016/j.bbamem.2020.183296 32268133
85. Milatz S. Piontek J. Schulzke J.D. Blasig I.E. Fromm M. Gunzel D. Probing the cis-arrangement of prototype tight junction proteins claudin-1 and claudin-3 Biochem. J. 2015 468 449 458 10.1042/BJ20150148 25849148
86. Dabrowski S. Staat C. Zwanziger D. Sauer R.S. Bellmann C. Guenther R. Krause E. Haseloff R.F. Rittner H. Blasig I.E. Redox-Sensitive Structure and Function of the First Extracellular Loop of the Cell-Cell Contact Protein Claudin-1: Lessons from Molecular Structure to Animals Antioxid. Redox Signal. 2015 22 1 14 10.1089/ars.2013.5706 24988310
87. Piontek J. Fritzsche S. Cording J. Richter S. Hartwig J. Walter M. Yu D. Turner J.R. Gehring C. Rahn H.P. Elucidating the principles of the molecular organization of heteropolymeric tight junction strands Cell. Mol. Life Sci. 2011 68 3903 3918 10.1007/s00018-011-0680-z 21533891
88. Rajapakse H.E. Gahlaut N. Mohandessi S. Yu D. Turner J.R. Miller L.W. Time-resolved luminescence resonance energy transfer imaging of protein-protein interactions in living cells Proc. Natl. Acad. Sci. USA 2010 107 13582 13587 10.1073/pnas.1002025107 20643966
89. Akimoto T. Takasawa A. Takasawa K. Aoyama T. Murata M. Osanai M. Saito T. Sawada N. Estrogen/GPR30 Signaling Contributes to the Malignant Potentials of ER-Negative Cervical Adenocarcinoma via Regulation of Claudin-1 Expression Neoplasia 2018 20 1083 1093 10.1016/j.neo.2018.08.010 30227306
90. Upmanyu N. Bulldan A. Papadopoulos D. Dietze R. Malviya V.N. Scheiner-Bobis G. Impairment of the Gn alpha 11-controlled expression of claudin-1 and MMP-9 and collective migration of human breast cancer MCF-7 cells by DHEAS J. Steroid Biochem. Mol. Biol. 2018 182 50 61 10.1016/j.jsbmb.2018.04.010 29684479
91. Saeedi B.J. Kao D.J. Kitzenberg D.A. Dobrinskikh E. Schwisow K.D. Masterson J.C. Kendrick A.A. Kelly C.J. Bayless A.J. Kominsky D.J. HIF-dependent regulation of claudin-1 is central to intestinal epithelial tight junction integrity Mol. Biol. Cell 2015 26 2252 2262 10.1091/mbc.E14-07-1194 25904334
92. Ishizaki T. Chiba H. Kojima T. Fujibe M. Soma T. Miyajima H. Nagasawa K. Wada I. Sawada N. Cyclic AMP induces phosphorylation of claudin-5 immunoprecipitates and expression of claudin-5 gene in blood-brain-barrier endothelial cells via protein kinase A-dependent and -independent pathways Exp. Cell Res. 2003 290 275 288 10.1016/S0014-4827(03)00354-9 14567987
93. Ishihara H. Kubota H. Lindberg R.L.P. Leppert D. Gloor S.M. Errede M. Virgintino D. Fontana A. Yonekawa Y. Frei K. Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta(2) involves matrix metalloproteinases and tight junction proteins J. Neuropathol. Exp. Neurol. 2008 67 435 448 10.1097/NEN.0b013e31816fd622 18431253
94. Wang J. Chen J.Q. Tang Z.X. Li Y. Hu L.M. Pan J.Q. The Effects of Copper on Brain Microvascular Endothelial Cells and Claudin Via Apoptosis and Oxidative Stress Biol. Trace Elem. Res. 2016 174 132 141 10.1007/s12011-016-0685-4 27038183
95. Burek M. Konig A. Lang M. Fiedler J. Oerter S. Roewer N. Bohnert M. Thal S.C. Blecharz-Lang K.G. Woitzik J. Hypoxia-Induced MicroRNA-212/132 Alter Blood-Brain Barrier Integrity Through Inhibition of Tight Junction-Associated Proteins in Human and Mouse Brain Microvascular Endothelial Cells Transl. Stroke Res. 2019 10 672 683 10.1007/s12975-018-0683-2 30617994
96. Velandia-Romero M.L. Calderon-Pelaez M.A. Castellanos J.E. In Vitro Infection with Dengue Virus Induces Changes in the Structure and Function of the Mouse Brain Endothelium PLoS ONE 2016 11 e0157786 10.1371/journal.pone.0157786 27336851
97. Blackmon A.M. Como C.N. Bubak A.N. Mescher T. Jones D. Nagel M.A. Varicella Zoster Virus Alters Expression of Cell Adhesion Proteins in Human Perineurial Cells via Interleukin 6 J. Infect. Dis. 2019 220 1453 1461 10.1093/infdis/jiz095 30835269
98. Yumine N. Matsumoto Y. Ohta K. Fukasawa M. Nishio M. Claudin-1 inhibits human parainfluenza virus type 2 dissemination Virology 2019 531 93 99 10.1016/j.virol.2019.01.031 30856486
99. Tian T. Zi X. Peng Y. Wang Z. Hong H. Yan Y. Guan W. Tan K.S. Liu J. Ong H.H. H3N2 influenza virus infection enhances oncostatin M expression in human nasal epithelium Exp. Cell Res. 2018 371 322 329 10.1016/j.yexcr.2018.08.022 30142324
100. Kast J.I. McFarlane A.J. Globinska A. Sokolowska M. Wawrzyniak P. Sanak M. Schwarze J. Akdis C.A. Wanke K. Respiratory syncytial virus infection influences tight junction integrity Clin. Exp. Immunol. 2017 190 351 359 10.1111/cei.13042 28856667
101. Wachter B. Schurger S. Schmid A. Groger A. Sadler R. Speidel A. Rolinger J. Pichler B.J. Berg D. Wagner H.J. 6-Hydroxydopamine leads to T2 hyperintensity, decreased claudin-3 immunoreactivity and altered aquaporin 4 expression in the striatum Behav. Brain Res. 2012 232 148 158 10.1016/j.bbr.2012.04.005 22516842
102. Dias M.C. Coisne C. Lazarevic I. Baden P. Hata M. Iwamoto N. Francisco D.M.F. Vanlandewijck M. He L. Baier F.A. Publisher Correction: Claudin-3-deficient C57BL/6J mice display intact brain barriers Sci. Rep. 2019 9 10702 10.1038/s41598-019-43511-0 31320665
103. Hashimoto K. Oshima T. Tomita T. Kim Y. Matsumoto T. Joh T. Miwa H. Oxidative stress induces gastric epithelial permeability through claudin-3 Biochem. Biophys. Res. Commun. 2008 376 154 157 10.1016/j.bbrc.2008.08.140 18774778
104. Zuo S.L. Ge H.F. Li Q. Zhang X. Hu R. Hu S.L. Liu X. Zhang J.H. Chen Y.J. Feng H. Artesunate Protected Blood-Brain Barrier via Sphingosine 1 Phosphate Receptor 1/Phosphatidylinositol 3 Kinase Pathway After Subarachnoid Hemorrhage in Rats Mol. Neurobiol. 2017 54 1213 1228 10.1007/s12035-016-9732-6 26820677
105. Liebner S. Corada M. Bangsow T. Babbage J. Taddei A. Czupalla C.J. Reis M. Felici A. Wolburg H. Fruttiger M. Wnt/beta-catenin signaling controls development of the blood-brain barrier J. Cell Biol. 2008 183 409 417 10.1083/jcb.200806024 18955553
106. Furuse M. Sasaki H. Tsukita S. Manner of interaction of heterogeneous claudin species within and between tight junction strands J. Cell Biol. 1999 147 891 903 10.1083/jcb.147.4.891 10562289
107. Markov A.G. Fedorova A.A. Kravtsova V.V. Bikmurzina A.E. Okorokova L.S. Matchkov V.V. Cornelius V. Amasheh S. Krivoi I.I. Circulating Ouabain Modulates Expression of Claudins in Rat Intestine and Cerebral Blood Vessels Int. J. Mol. Sci. 2020 21 16 10.3390/ijms21145067 32709081
108. Ohtsuki S. Ikeda C. Uchida Y. Sakamoto Y. Miller F. Glacial F. Decleves X. Scherrmann J.M. Couraud P.O. Kubo Y. Quantitative Targeted Absolute Proteomic Analysis of Transporters, Receptors and Junction Proteins for Validation of Human Cerebral Microvascular Endothelial Cell Line hCMEC/D3 as a Human Blood-Brain Barrier Model Mol. Pharm. 2013 10 289 296 10.1021/mp3004308 23137377
109. Ek C.J. Dziegielewska K.M. Stolp H. Saunders N.R. Functional effectiveness of the blood brain barrier to small water-soluble molecules in developing and adult opossum (Monodelphis domestica) J. Comp. Neurol. 2006 496 13 26 10.1002/cne.20885 16528724
110. Luissint A.C. Federici C. Guillonneau F. Chretien F. Camoin L. Glacial F. Ganeshamoorthy K. Couraud P.O. Guanine nucleotide-binding protein G alpha i2: A new partner of claudin-5 that regulates tight junction integrity in human brain endothelial cells J. Cereb. Blood Flow Metab. 2012 32 860 873 10.1038/jcbfm.2011.202 22333621
111. Mandel I. Paperna T. Volkowich A. Merhav M. Glass-Marmor L. Miller A. The Ubiquitin-Proteasome Pathway Regulates Claudin 5 Degradation J. Cell. Biochem. 2012 113 2415 2423 10.1002/jcb.24118 22389112
112. Honda M. Nakagawa S. Hayashi K. Kitagawa N. Tsutsumi K. Nagata I. Niwa M. Adrenomedullin improves the blood-brain barrier function through the expression of claudin-5 Cell. Mol. Neurobiol. 2006 26 109 118 10.1007/s10571-006-9028-x 16763778
113. Wen H.J. Watry D.D. Marcondes M.C.G. Fox H.S. Selective decrease in paracellular conductance of tight junctions: Role of the first extracellular domain of claudin-5 Mol. Cell. Biol. 2004 24 8408 8417 10.1128/MCB.24.19.8408-8417.2004 15367662
114. Sasson E. Anzi S. Bell B. Yakovian O. Zorsky M. Deutsch U. Engelhardt B. Sherman E. Vatine G. Dzikowski R. Nano-scale architecture of blood-brain barrier tight-junctions eLife 2021 10 e63253 10.7554/eLife.63253 34951586
115. Hashimoto Y. Poirier K. Boddaert N. Hubert L. Aubart M. Kaminska A. Alison M. Desguerre I. Munnich A. Campbell M. Recurrent de novo mutations in CLDN5 induce an anion-selective blood-brain barrier and alternating hemiplegia Brain 2022 145 3374 3382 10.1093/brain/awac215 35714222
116. Krajewski D. Paul D. Ge S. Jellison E. Pachter J.S. Appearance of claudin-5(+) leukocyte subtypes in the blood and CNS during progression of EAE J. Neuroinflamm. 2021 18 296 10.1186/s12974-021-02328-3 34933669
117. Soma T. Chiba H. Kato-Mori Y. Wada T. Yamashita T. Kojima T. Sawada N. Thr(207) of claudin-5 is involved in size-selective loosening of the endothelial barrier by cyclic AMP Exp. Cell Res. 2004 300 202 212 10.1016/j.yexcr.2004.07.012 15383327
118. Watabe T. Nishihara A. Mishima K. Yamashita J. Shimizu K. Miyazawa K. Nishikawa S. Miyazono K. TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells J. Cell Biol. 2003 163 1303 1311 10.1083/jcb.200305147 14676305
119. Taddei A. Giampietro C. Conti A. Orsenigo F. Breviario F. Pirazzoli V. Potente M. Daly C. Dimmeler S. Dejana E. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5 Nat. Cell Biol. 2008 10 923 934 10.1038/ncb1752 18604199
120. Sadowska G.B. Malaeb S.N. Stonestreet B.S. Maternal glucocorticoid exposure alters tight junction protein expression in the brain of fetal sheep Am. J. Physiol. Heart Circ. Physiol. 2010 298 H179 H188 10.1152/ajpheart.00828.2009 19855054
121. Felinski E.A. Cox A.E. Phillips B.E. Antonetti D.A. Glucocorticoids induce transactivation of tight junction genes occludin and claudin-5 in retinal endothelial cells via a novel cis-element Exp. Eye Res. 2008 86 867 878 10.1016/j.exer.2008.01.002 18501346
122. Burek M. Arias-Loza P.A. Roewer N. Forster C.Y. Claudin-5 as a Novel Estrogen Target in Vascular Endothelium Arterioscler. Thromb. Vasc. Biol. 2010 30 298 304 10.1161/ATVBAHA.109.197582 19910637
123. Zhao Y.L. Li W.M. Song J.N. Zhang M. Huang T.Q. Wei X. High expression of EphA2 led to secondary injury by destruction of BBB integrity though the ROCK pathway after diffuse axonal injury Neurosci. Lett. 2020 736 10 10.1016/j.neulet.2020.135234 32721428
124. Lee E.C. Hong D.Y. Lee D.H. Park S.W. Lee J.Y. Jeong J.H. Kim E.Y. Chung H.M. Hong K.S. Park S.P. Inflammation and Rho-Associated Protein Kinase-Induced Brain Changes in Vascular Dementia Biomedicines 2022 10 446 10.3390/biomedicines10020446 35203655
125. Kakogiannos N. Ferrari L. Giampietro C. Scalise A.A. Maderna C. Rava M. Taddei A. Lampugnani M.G. Pisati F. Malinverno M. JAM-A Acts via C/EBP-alpha to Promote Claudin-5 Expression and Enhance Endothelial Barrier Function Circ. Res. 2020 127 1056 1073 10.1161/CIRCRESAHA.120.316742 32673519
126. Bilgic A. Ferahkaya H. Karagoz H. Kilinc I. Energin V.M. Serum claudin-5, claudin-11, occludin, vinculin, paxillin, and beta-catenin levels in preschool children with autism spectrum disorder Nord. J. Psychiatry 2023 77 506 511 10.1080/08039488.2023.2168055 36662163
127. Kazmierski R. Michalak S. Wencel-Warot A. Nowinski W.L. Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients Neurology 2012 79 1677 1685 10.1212/WNL.0b013e31826e9a83 22993287
128. Cash A. de Jager C. Brickler T. Soliman E. Ladner L. Kaloss A.M. Zhu Y. Pridham K.J. Mills J. Ju J. Endothelial deletion of EPH receptor A4 alters single-cell profile and Tie2/Akap12 signaling to preserve blood-brain barrier integrity Proc. Natl. Acad. Sci. USA 2023 120 e2204700120 10.1073/pnas.2204700120 37796990
129. Qiao N. An Z. Fu Z. Chen X. Tong Q. Zhang Y. Ren H. Kinsenoside alleviates oxidative stress-induced blood-brain barrier dysfunction via promoting Nrf2/HO-1 pathway in ischemic stroke Eur. J. Pharmacol. 2023 949 175717 10.1016/j.ejphar.2023.175717 37054938
130. Uchida Y. Sumiya T. Tachikawa M. Yamakawa T. Murata S. Yagi Y. Sato K. Stephan A. Ito K. Ohtsuki S. Involvement of Claudin-11 in Disruption of Blood-Brain, -Spinal Cord, and -Arachnoid Barriers in Multiple Sclerosis Mol. Neurobiol. 2019 56 2039 2056 10.1007/s12035-018-1207-5 29984400
131. Chow E. Mottahedeh J. Prins M. Ridder W. Nusinowitz S. Bronstein J.M. Disrupted compaction of CNS myelin in an OSP/claudin-11 and PLP/DM20 double knockout mouse Mol. Cell. Neurosci. 2005 29 405 413 10.1016/j.mcn.2005.03.007 15886014
132. Ruan Z. Cao G. Qian Y. Fu L. Hu J. Xu T. Wu Y. Lv Y. Single-cell RNA sequencing unveils Lrg1’s role in cerebral ischemia—reperfusion injury by modulating various cells J. Neuroinflamm. 2023 20 285 10.1186/s12974-023-02941-4 38037097
133. Cording J. Gunther R. Vigolo E. Tscheik C. Winkler L. Schlattner I. Lorenz D. Haseloff R.F. Schmidt-Ott K.M. Wolburg H. Redox Regulation of Cell Contacts by Tricellulin and Occludin: Redox-Sensitive Cysteine Sites in Tricellulin Regulate Both Tri- and Bicellular Junctions in Tissue Barriers as Shown in Hypoxia and Ischemia Antioxid. Redox Signal. 2015 23 1035 1049 10.1089/ars.2014.6162 25919114
134. Tezuka K. Suzuki M. Sato R. Kawarada S. Terasaki T. Uchida Y. Activation of Annexin A2 signaling at the blood-brain barrier in a mouse model of multiple sclerosis J. Neurochem. 2022 160 662 674 10.1111/jnc.15578 35064931
135. Nagano H. Ogata S. Ito S. Masuda T. Ohtsuki S. Knockdown of Podocalyxin Post-Transcriptionally Induces the Expression and Activity of ABCB1/MDR1 in Human Brain Microvascular Endothelial Cells J. Pharm. Sci. 2022 111 1812 1819 10.1016/j.xphs.2022.02.006 35182544
136. Ohtsuki S. Yamaguchi H. Katsukura Y. Asashima T. Terasaki T. mRNA expression levels of tight junction protein genes in mouse brain capillary endothelial cells highly purified by magnetic cell sorting J. Neurochem. 2008 104 147 154 10.1111/j.1471-4159.2007.05008.x 17971126
137. Castro Dias M. Coisne C. Baden P. Enzmann G. Garrett L. Becker L. Holter S.M. German Mouse Clinic C. Hrabe de Angelis M. Deutsch U. Claudin-12 is not required for blood-brain barrier tight junction function Fluids Barriers CNS 2019 16 30 10.1186/s12987-019-0150-9 31511021
138. Furuse M. Nakatsu D. Hempstock W. Sugioka S. Ishizuka N. Furuse K. Sugawara T. Fukazawa Y. Hayashi H. Reconstitution of functional tight junctions with individual claudin subtypes in epithelial cells Cell Struct. Funct. 2023 48 1 17 10.1247/csf.22068 36504093
139. Kanoski S.E. Zhang Y.S. Zheng W. Davidson T.L. The Effects of a High-Energy Diet on Hippocampal Function and Blood-Brain Barrier Integrity in the Rat J. Alzheimers Dis. 2010 21 207 219 10.3233/JAD-2010-091414 20413889
140. Belanger M. Asashima T. Ohtsuki S. Yamaguchi H. Ito S. Terasaki T. Hyperammonemia induces transport of taurine and creatine and suppresses claudin-12 gene expression in brain capillary endothelial cells in vitro Neurochem. Int. 2007 50 95 101 10.1016/j.neuint.2006.07.005 16956696
141. Salameh T.S. Mortell W.G. Logsdon A.F. Butterfield D.A. Banks W.A. Disruption of the hippocampal and hypothalamic blood-brain barrier in a diet-induced obese model of type II diabetes: Prevention and treatment by the mitochondrial carbonic anhydrase inhibitor, topiramate Fluids Barriers CNS 2019 16 17 10.1186/s12987-018-0121-6 31189484
142. Hao N. Lee K.L. Furness S.G.B. Bosdotter C. Poellinger L. Whitelaw M.L. Xenobiotics and Loss of Cell Adhesion Drive Distinct Transcriptional Outcomes by Aryl Hydrocarbon Receptor Signaling Mol. Pharmacol. 2012 82 1082 1093 10.1124/mol.112.078873 22936816
143. Matsuoka H. Shima A. Uda A. Ezaki H. Michihara A. The retinoic acid receptor-related orphan receptor alpha positively regulates tight junction protein claudin domain-containing 1 mRNA expression in human brain endothelial cells J. Biochem. 2017 161 441 450 28130419
144. Shima A. Matsuoka H. Yamaoka A. Michihara A. Transcription of CLDND1 in human brain endothelial cells is regulated by the myeloid zinc finger 1 Clin. Exp. Pharmacol. Physiol. 2021 10 260 269 10.1111/1440-1681.13416 33037622
145. Matsuoka H. Tamura A. Kinehara M. Shima A. Uda A. Tahara H. Michihara A. Levels of tight junction protein CLDND1 are regulated by microRNA-124 in the cerebellum of stroke-prone spontaneously hypertensive rats Biochem. Biophys. Res. Commun. 2018 498 817 823 10.1016/j.bbrc.2018.03.063 29530526
146. Abbott N.J. Patabendige A.A.K. Dolman D.E.M. Yusof S.R. Begley D.J. Structure and function of the blood-brain barrier Neurobiol. Dis. 2010 37 13 25 10.1016/j.nbd.2009.07.030 19664713
147. Mathiisen T.M. Lehre K.P. Danbolt N.C. Ottersen O.P. The Perivascular Astroglial Sheath Provides a Complete Covering of the Brain Microvessels: An Electron Microscopic 3D Reconstruction Glia 2010 58 1094 1103 10.1002/glia.20990 20468051
148. Readnower R.D. Chavko M. Adeeb S. Conroy M.D. Pauly J.R. McCarron R.M. Sullivan P.G. Increase in Blood-Brain Barrier Permeability, Oxidative Stress, and Activated Microglia in a Rat Model of Blast-Induced Traumatic Brain Injury J. Neurosci. Res. 2010 88 3530 3539 10.1002/jnr.22510 20882564
149. Zhao Y.N. Wang F. Fan Y.X. Ping G.F. Yang J.Y. Wu C.F. Activated microglia are implicated in cognitive deficits, neuronal death, and successful recovery following intermittent ethanol exposure Behav. Brain Res. 2013 236 270 282 10.1016/j.bbr.2012.08.052 22985845
150. Abbott N.J. Ronnback L. Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier Nat. Rev. Neurosci. 2006 7 41 53 10.1038/nrn1824 16371949
151. Begley D.J. Understanding and circumventing the blood-brain barrier Acta Paediatr. 2003 92 83 91 10.1111/j.1651-2227.2003.tb00226.x 14989470
152. Cecchelli R. Berezowski V. Lundquist S. Culot M. Renftel M. Dehouck M.P. Fenart L. Modelling of the blood-brain barrier in drug discovery and development Nat. Rev. Drug Discov. 2007 6 650 661 10.1038/nrd2368 17667956
153. Risau W. Wolburg H. Development of the blood-brain-barrier Trends Neurosci. 1990 13 174 178 10.1016/0166-2236(90)90043-A 1693235
154. Wolburg H. Lippoldt A. Tight junctions of the blood-brain barrier: Development, composition and regulation Vasc. Pharmacol. 2002 38 323 337 10.1016/S1537-1891(02)00200-8 12529927
155. Liebner S. Dijkhuizen R.M. Reiss Y. Plate K.H. Agalliu D. Constantin G. Functional morphology of the blood-brain barrier in health and disease Acta Neuropathol. 2018 135 311 336 10.1007/s00401-018-1815-1 29411111
156. Kimelberg H.K. Water homeostasis in the brain: Basic concepts Neuroscience 2004 129 851 860 10.1016/j.neuroscience.2004.07.033 15561403
157. Fraser P.A. Dallas A.D. Davies S. Measurement of filtration coefficient in single cerebral microvessels of the frog J. Physiol. 1990 423 343 361 10.1113/jphysiol.1990.sp018026 2388154
158. Butt A.M. Jones H.C. Abbott N.J. Electrical resistance across the blood-brain-barrier in anesthetized rats—A developmental-study J. Physiol. 1990 429 47 62 10.1113/jphysiol.1990.sp018243 2277354
159. Lauschke K. Frederiksen L. Hall V.J. Paving the Way toward Complex Blood-Brain Barrier Models Using Pluripotent Stem Cells Stem Cells Dev. 2017 26 857 874 10.1089/scd.2017.0003 28398169
160. Villegas J.C. Broadwell R.D. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. II. Adsorptive transcytosis of WGA-HRP and the blood-brain and brain blood barriers J. Neurocytol. 1993 22 67 80 10.1007/BF01181571 7680372
161. Lochhead J.J. Yang J.Z. Ronaldson P.T. Davis T.P. Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders Front. Physiol. 2020 11 17 10.3389/fphys.2020.00914 32116742
162. Mark K.S. Davis T.P. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation Am. J. Physiol. Heart Circ. Physiol. 2002 282 H1485 H1494 10.1152/ajpheart.00645.2001 11893586
163. van der Goes A. Wouters D. van der Pol S.M.A. Huizinga R. Ronken E. Adamson P. Greenwood J. Dijkstra C.D. de Vries H.E. Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier in vitro FASEB J. 2001 15 1852 1854 10.1096/fj.00-0881fje 11481252
164. El-Bacha R.S. Minn A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain Cell. Mol. Biol. 1999 45 15 23 10099836
165. Lipinski C.A. Lombardo F. Dominy B.W. Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 1997 23 3 25 10.1016/S0169-409X(96)00423-1
166. Hladky S.B. Barrand M.A. Fluid and ion transfer across the blood-brain and blood-cerebrospinal fluid barriers; a comparative account of mechanisms and roles Fluids Barriers CNS 2016 13 19 10.1186/s12987-016-0040-3 27799072
167. Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems NeuroRx 2005 2 54 62 10.1602/neurorx.2.1.54 15717057
168. Nalecz K.A. Solute Carriers in the Blood-Brain Barier: Safety in Abundance Neurochem. Res. 2017 42 795 809 10.1007/s11064-016-2030-x 27503090
169. Morris M.E. Rodriguez-Cruz V. Felmlee M.A. SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers AAPS J. 2017 19 1317 1331 10.1208/s12248-017-0110-8 28664465
170. Gao P. Stieger B. Noe B. Fritschy J.M. Meier P.J. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain J. Histochem. Cytochem. 1999 47 1255 1263 10.1177/002215549904701005 10490454
171. Thompson B.J. Sanchez-Covarrubias L. Slosky L.M. Zhang Y.F. Laracuente M.L. Ronaldson P.T. Hypoxia/reoxygenation stress signals an increase in organic anion transporting polypeptide 1a4 (Oatp1a4) at the blood-brain barrier: Relevance to CNS drug delivery J. Cereb. Blood Flow Metab. 2014 34 699 707 10.1038/jcbfm.2014.4 24473481
172. Hagenbuch B. Meier P.J. The superfamily of organic anion transporting polypeptides Biochim. Biophys. Acta Biomembr. 2003 1609 1 18 10.1016/S0005-2736(02)00633-8 12507753
173. Prasad S. Sajja R.K. Naik P. Cucullo L. Diabetes Mellitus and Blood-Brain Barrier Dysfunction: An Overview J. Pharmacovigil. 2014 2 125 25632404
174. Zhao Y.H. Li D.D. Zhao J.J. Song J.N. Zhao Y.L. The role of the low-density lipoprotein receptor-related protein 1 (LRP-1) in regulating blood-brain barrier integrity Rev. Neurosci. 2016 27 623 634 10.1515/revneuro-2015-0069 27206317
175. Zhang Y. Pardridge W.M. Rapid transferrin efflux from brain to blood across the blood-brain barrier J. Neurochem. 2001 76 1597 1600 10.1046/j.1471-4159.2001.00222.x 11238745
176. Bjorbaek C. Elmquist J.K. Michl P. Ahima R.S. van Bueren A. McCall A.L. Flier J.S. Expression of leptin receptor isoforms in rat brain microvessels Endocrinology 1998 139 3485 3491 10.1210/endo.139.8.6154 9681499
177. Moura R.P. Martins C. Pinto S. Sousa F. Sarmento B. Blood-brain barrier receptors and transporters: An insight on their function and how to exploit them through nanotechnology Expert Opin. Drug Deliv. 2019 16 271 285 10.1080/17425247.2019.1583205 30767695
178. Wang Q. Yang H. Miller D.W. Elmquist W.F. Effect of the P-Glycoprotein Inhibitor, Cyclosporine-A, on the Distribution of Rhodamine-123 to the Brain—An in-vivo Microdialysis Study in Freely Moving Rats Biochem. Biophys. Res. Commun. 1995 211 719 726 10.1006/bbrc.1995.1872 7598699
179. Sparreboom A. vanAsperen J. Mayer U. Schinkel A.H. Smit J.W. Meijer D.K.F. Borst P. Nooijen W.J. Beijnen J.H. vanTellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc. Natl. Acad. Sci. USA 1997 94 2031 2035 10.1073/pnas.94.5.2031 9050899
180. Ohnishi T. Tamai I. Sakanaka K. Sakata A. Yamashima T. Yamashita J. Tsuji A. In vivo and in vitro evidence for ATP dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier Biochem. Pharmacol. 1995 49 1541 1544 10.1016/0006-2952(95)00082-B 7763297
181. Loscher W. Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters Nat. Rev. Neurosci. 2005 6 591 602 10.1038/nrn1728 16025095
182. Brooks T.A. Hawkins B.T. Huber J.D. Egleton R.D. Davis T.P. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations Am. J. Physiol. Heart Circ. Physiol. 2005 289 H738 H743 10.1152/ajpheart.01288.2004 15792985
183. Morita K. Sasaki H. Furuse M. Tsukita S. Endothelial claudin: Claudin-5/TMVCF constitutes tight junction strands in endothelial cells J. Cell Biol. 1999 147 185 194 10.1083/jcb.147.1.185 10508865
184. Amasheh S. Schmidt T. Mahn M. Florian P. Mankertz J. Tavalali S. Gitter A. Schulzke J.D. Fromm M. Contribution of claudin-5 to barrier properties in tight junctions of epithelial cells Cell Tissue Res. 2005 321 89 96 10.1007/s00441-005-1101-0 16158492
185. Campbell M. Kiang A.S. Kenna P.F. Kerskens C. Blau C. O’Dwyer L. Tivnan A. Kelly J.A. Brankin B. Farrar G.J. RNAi-mediated reversible opening of the blood-brain barrier J. Gene. Med. 2008 10 930 947 10.1002/jgm.1211 18509865
186. Berselli A. Alberini G. Benfenati F. Maragliano L. The impact of pathogenic and artificial mutations on Claudin-5 selectivity from molecular dynamics simulations Comput. Struct. Biotechnol. J. 2023 21 2640 2653 10.1016/j.csbj.2023.04.001 37138900
187. Rossa J. Ploeger C. Vorreiter F. Saleh T. Protze J. Gunzel D. Wolburg H. Krause G. Piontek J. Claudin-3 and Claudin-5 Protein Folding and Assembly into the Tight Junction Are Controlled by Non-conserved Residues in the Transmembrane 3 (TM3) and Extracellular Loop 2 (ECL2) Segments J. Biol. Chem. 2014 289 7641 7653 10.1074/jbc.M113.531012 24478310
188. Wolburg H. Noell S. Mack A. Wolburg-Buchholz K. Fallier-Becker P. Brain endothelial cells and the glio-vascular complex Cell Tissue Res. 2009 335 75 96 10.1007/s00441-008-0658-9 18633647
189. Ramirez S.H. Fan S.S. Dykstra H. Rom S. Mercer A. Reichenbach N.L. Gofman L. Persidsky Y. Inhibition of Glycogen Synthase Kinase 3 beta Promotes Tight Junction Stability in Brain Endothelial Cells by Half-Life Extension of Occludin and Claudin-5 PLoS ONE 2013 8 e55972 10.1371/journal.pone.0055972 23418486
190. Bocsik A. Walter F.R. Gyebrovszki A. Fulop L. Blasig I. Dabrowski S. Otvos F. Toth A. Rakhely G. Veszelka S. Reversible Opening of Intercellular Junctions of Intestinal Epithelial and Brain Endothelial Cells With Tight Junction Modulator Peptides J. Pharm. Sci. 2016 105 754 765 10.1016/j.xphs.2015.11.018 26869428
191. Wu J.W. Yang Y.S. Zhang J.H. Ji P. Du W.J. Jiang P. Xie D.H. Huang H.D. Wu M. Zhang G.Z. Domain-swapped dimerization of the second PDZ domain of ZO2 may provide a structural basis for the polymerization of claudins J. Biol. Chem. 2007 282 35988 35999 10.1074/jbc.M703826200 17897942
192. Torices S. Roberts S.A. Park M. Malhotra A. Toborek M. Occludin, caveolin-1, and Alix form a multi-protein complex and regulate HIV-1 infection of brain pericytes Faseb J. 2020 34 16319 16332 10.1096/fj.202001562R 33058236
193. Koval M. Claudin Heterogeneity and Control of Lung Tight Junctions Ann. Rev. Physiol. 2013 75 551 567 23072447
194. Wollscheid B. Bausch-Fluck D. Henderson C. O’Brien R. Bibel M. Schiess R. Aebersold R. Watts J.D. Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins Nat. Biotechnol. 2009 27 378 386 10.1038/nbt.1532 19349973
195. Moremen K.W. Tiemeyer M. Nairn A.V. Vertebrate protein glycosylation: Diversity, synthesis and function Nat. Rev. Mol. Cell Biol. 2012 13 448 462 10.1038/nrm3383 22722607
196. Wang X.H. Matsumoto H. Zhao X.M. Das S.K. Paria B.C. Embryonic signals direct the formation of tight junctional permeability barrier in the decidualizing stroma during embryo implantation J. Cell Sci. 2004 117 53 62 10.1242/jcs.00826 14627626
197. Paganelli M. Stephenne X. Gilis A. Jacquemin E. Henrion-Caude A. Girard M. Gonzales E. Revencu N. Reding R. Wanty C. Neonatal Ichthyosis and Sclerosing Cholangitis Syndrome: Extremely Variable Liver Disease Severity from Claudin-1 Deficiency J. Pediatr. Gastroenterol. Nutr. 2011 53 350 354 10.1097/MPG.0b013e3182169433 21865982
198. Staat C. Coisne C. Dabrowski S. Stamatovic S.M. Andjelkovic A.V. Wolburg H. Engelhardt B. Blasig I.E. Mode of action of claudin peptidomimetics in the transient opening of cellular tight junction barriers Biomaterials 2015 54 9 20 10.1016/j.biomaterials.2015.03.007 25907035
199. Dithmer S. Staat C. Muller C. Ku M.C. Pohlmann A. Niendorf T. Gehne N. Fallier-Becker P. Kittel A. Walter F.R. Claudin peptidomimetics modulate tissue barriers for enhanced drug delivery Ann. N. Y. Acad. Sci. 2017 1397 169 184 10.1111/nyas.13359 28505395
200. Tornabene E. Helms H.C.C. Pedersen S.F. Brodin B. Effects of oxygen-glucose deprivation (OGD) on barrier properties and mRNA transcript levels of selected marker proteins in brain endothelial cells/astrocyte co-cultures PLoS ONE 2019 14 e0221103 10.1371/journal.pone.0221103 31425564
201. Furuse M. Hirase T. Itoh M. Nagafuchi A. Yonemura S. Tsukita S. Tsukita S. Occludin—A novel integral membrane-protein localizing at tight junctions J. Cell Biol. 1993 123 1777 1788 10.1083/jcb.123.6.1777 8276896
202. Wong V. Phosphorylation of occludin correlates with occludin localization and function at the tight junction Am. J. Physiol. 1997 273 C1859 C1867 10.1152/ajpcell.1997.273.6.C1859 9435490
203. Iwamoto N. Higashi T. Furuse M. Localization of Angulin-1/LSR and Tricellulin at Tricellular Contacts of Brain and Retinal Endothelial Cells in vivo Cell Struct. Funct. 2014 39 1 8 10.1247/csf.13015 24212375
204. Bellmann C. Schreivogel S. Gunther R. Dabrowski S. Schumann M. Wolburg H. Blasig I.E. Highly Conserved Cysteines Are Involved in the Oligomerization of Occludin-Redox Dependency of the Second Extracellular Loop Antioxid. Redox Signal. 2014 20 855 867 10.1089/ars.2013.5288 23923978
205. Blasig I.E. Bellmann C. Cording J. del Vecchio G. Zwanziger D. Huber O. Haseloff R.F. Occludin Protein Family: Oxidative Stress and Reducing Conditions Antioxid. Redox Signal. 2011 15 1195 1219 10.1089/ars.2010.3542 21235353
206. Bosse F. Hasse B. Pippirs U. Greiner-Petter R. Muller H.W. Proteolipid plasmolipin: Localization in polarized cells, regulated expression and lipid raft association in CNS and PNS myelin J. Neurochem. 2003 86 508 518 10.1046/j.1471-4159.2003.01870.x 12871592
207. Balda M.S. Whitney J.A. Flores C. Gonzalez S. Cereijido M. Matter K. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein J. Cell Biol. 1996 134 1031 1049 10.1083/jcb.134.4.1031 8769425
208. Hirase T. Staddon J.M. Saitou M. AndoAkatsuka Y. Itoh M. Furuse M. Fujimoto K. Tsukita S. Rubin L.L. Occludin as a possible determinant of tight junction permeability in endothelial cells J. Cell Sci. 1997 110 1603 1613 10.1242/jcs.110.14.1603 9247194
209. Saito A.C. Higashi T. Fukazawa Y. Otani T. Tauchi M. Higashi A.Y. Furuse M. Chiba H. Occludin and tricellulin facilitate formation of anastomosing tight-junction strand network to improve barrier function Mol. Biol. Cell 2021 32 722 738 10.1091/mbc.E20-07-0464 33566640
210. Kojima T. Ninomiya T. Konno T. Kohno T. Taniguchi M. Sawada N. Expression of tricellulin in epithelial cells and non-epithelial cells Histol. Histopath. 2013 28 1383 1392
211. Krug S.M. Amasheh S. Richter J.F. Milatz S. Gunzel D. Westphal J.K. Huber O. Schulzke J.D. Fromm M. Tricellulin Forms a Barrier to Macromolecules in Tricellular Tight Junctions without Affecting Ion Permeability Mol. Biol. Cell 2009 20 3713 3724 10.1091/mbc.e09-01-0080 19535456
212. Saitou M. Furuse M. Sasaki H. Schulzke J.D. Fromm M. Takano H. Noda T. Tsukita S. Complex phenotype of mice lacking occludin, a component of tight junction strands Mol. Biol. Cell 2000 11 4131 4142 10.1091/mbc.11.12.4131 11102513
213. Schulzke J.D. Gitter A.H. Mankertz J. Spiegel S. Seidler U. Amasheh S. Saitou M. Tsukita S. Fromm M. Epithelial transport and barrier function in occludin-deficient mice Biochim. Biophys. Acta Biomembr. 2005 1669 34 42 10.1016/j.bbamem.2005.01.008 15842997
214. Walter J.K. Rueckert C. Voss M. Mueller S.L. Piontek J. Gast K. Blasig I.E. The oligomerization of the coiled coil-domain of occludin is redox sensitive Ann. N. Y. Acad. Sci 2009 1165 19 27 10.1111/j.1749-6632.2009.04058.x 19538283
215. Buschmann M.M. Shen L. Rajapakse H. Raleigh D.R. Wang Y.T. Wang Y.M. Lingaraju A. Zha J.M. Abbott E. McAuley E.M. Occludin OCEL-domain interactions are required for maintenance and regulation of the tight junction barrier to macromolecular flux Mol. Biol. Cell 2013 24 3056 3068 10.1091/mbc.e12-09-0688 23924897
216. Müller S.L. Portwich M. Schmidt A. Utepbergenov D.I. Huber O. Blasig I.E. Krause G. The tight junction protein occludin and the adherens junction protein alpha-catenin share a common interaction mechanism with ZO-1 J. Biol. Chem. 2005 280 3747 3756 10.1074/jbc.M411365200 15548514
217. Dorfel M.J. Huber O. A phosphorylation hotspot within the occludin C-terminal domain Barriers and Channels Formed by Tight Junction Proteins I Fromm M. Schulzke J.D. Blackwell Science Publishing Oxford, UK 2012 Volume 1257 38 44
218. Nusrat A. Chen J.A. Foley C.S. Liang T.W. Tom J. Cromwell M. Quan C. Mrsny R.J. The coiled-coil domain of occludin can act to organize structural and functional elements of the epithelial tight junction J. Biol. Chem. 2000 275 29816 29822 10.1074/jbc.M002450200 10887180
219. Andreeva A.Y. Krause E. Muller E.C. Blasig I.E. Utepbergenov D.I. Protein kinase C regulates the phosphorylation and cellular localization of occludin J. Biol. Chem. 2001 276 38480 38486 10.1074/jbc.M104923200 11502742
220. Reiche J. Huber O. Post-translational modifications of tight junction transmembrane proteins and their direct effect on barrier function Biochim. Biophys. Acta Biomembr. 2020 1862 183330 10.1016/j.bbamem.2020.183330 32376223
221. Li Y. Liu C. Chen Z. Lin H. Li X. Netrin-1 protects blood-brain barrier (BBB) integrity after cerebral ischemia-reperfusion by activating the Kruppel-like factor 2 (KLF2)/occludin pathway J. Biochem. Mol. Toxicol. 2024 38 e23623 10.1002/jbt.23623 38229322
222. Tash B.R. Bewley M.C. Russo M. Keil J.M. Griffin K.A. Sundstrom J.M. Antonetti D.A. Tian F. Flanagan J.M. The occludin and ZO-1 complex, defined by small angle X-ray scattering and NMR, has implications for modulating tight junction permeability Proc. Natl. Acad. Sci. USA 2012 109 10855 10860 10.1073/pnas.1121390109 22711802
223. Mariano C. Palmela I. Pereira P. Fernandes A. Falcao A.S. Cardoso F.L. Vaz A.R. Campos A.R. Goncalves-Ferreira A. Kim K.S. Tricellulin expression in brain endothelial and neural cells Cell Tissue Res. 2013 351 397 407 10.1007/s00441-012-1529-y 23250572
224. Tachibana K. Kondoh M. A Method to Prepare a Bioprobe for Regulatory Science of the Drug Delivery System to the Brain: An Angulin Binder to Modulate Tricellular Tight Junction-Seal Methods Mol. Biol. 2021 2367 291 304 32789775
225. Higashi T. Tokuda S. Kitajiri S. Masuda S. Nakamura H. Oda Y. Furuse M. Analysis of the ‘angulin’ proteins LSR, ILDR1 and ILDR2-tricellulin recruitment, epithelial barrier function and implication in deafness pathogenesis J. Cell Sci. 2013 126 966 977 10.1242/jcs.138271 23239027
226. Furuse M. Izumi Y. Oda Y. Higashi T. Iwamoto N. Molecular organization of tricellular tight junctions Tissue Barriers 2014 2 e28960 10.4161/tisb.28960 25097825
227. Mesli S. Javorschi S. Berard A.M. Landry M. Priddle H. Kivlichan D. Smith A.J. Yen F.T. Bihain B.E. Darmon M. Distribution of the lipolysis stimulated receptor in adult and embryonic murine tissues and lethality of LSR−/− embryos at 12.5 to 14.5 days of gestation Eur. J. Biochem. 2004 271 3103 3114 10.1111/j.1432-1033.2004.04223.x 15265030
228. Sohet F. Lin C. Munji R.N. Lee S.Y. Ruderisch N. Soung A. Arnold T.D. Derugin N. Vexler Z.S. Yen F.T. LSR/angulin-1 is a tricellular tight junction protein involved in blood-brain barrier formation J. Cell Biol. 2015 208 703 711 10.1083/jcb.201410131 25753034
229. Sugawara T. Furuse K. Otani T. Wakayama T. Furuse M. Angulin-1 seals tricellular contacts independently of tricellulin and claudins J. Cell Biol. 2021 220 e202005062 10.1083/jcb.202005062 34269802
230. Hori S. Ohtsuki S. Hosoya K. Nakashima E. Terasaki T. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro J. Neurochem. 2004 89 503 513 10.1111/j.1471-4159.2004.02343.x 15056293
231. Savettieri G. Di Liegro I. Catania C. Licata L. Pitarresi G.L. D’Agostino S. Schiera G. De Caro V. Giandalia G. Giannola L.I. Neurons and ECM regulate occludin localization in brain endothelial cells Neuroreport 2000 11 1081 1084 10.1097/00001756-200004070-00035 10790886
232. Bendriem R.M. Singh S. Aleem A.A. Antonetti D.A. Ross M.E. Tight junction protein occludin regulates progenitor Self-Renewal and survival in developing cortex eLife 2019 8 26 10.7554/eLife.49376 31794381
233. Kuo W.T. Shen L. Zuo L. Shashikanth N. Ong M. Wu L.C. Zha J.M. Edelblum K.L. Wang Y.T. Wang Y.M. Inflammation-induced Occludin Downregulation Limits Epithelial Apoptosis by Suppressing Caspase-3 Expression Gastroenterology 2019 157 1323 1337 10.1053/j.gastro.2019.07.058 31401143
234. Castro V. Bertrand L. Luethen M. Dabrowski S. Lombardi J. Morgan L. Sharova N. Stevenson M. Blasig I.E. Toborek M. Occludin controls HIV transcription in brain pericytes via regulation of SIRT-1 activation FASEB J. 2016 30 1234 1246 10.1096/fj.15-277673 26601824
235. Castro V. Skowronska M. Lombardi J. He J. Seth N. Velichkovska M. Toborek M. Occludin regulates glucose uptake and ATP production in pericytes by influencing AMP-activated protein kinase activity J. Cereb. Blood Flow Metab. 2018 38 317 332 10.1177/0271678X17720816 28718701
236. Van Itallie C.M. Fanning A.S. Holmes J. Anderson J.M. Occludin is required for cytokine-induced regulation of tight junction barriers J. Cell Sci. 2010 123 2844 2852 10.1242/jcs.065581 20663912
237. Li Y.H. Fanning A.S. Anderson J.M. Lavie A. Structure of the conserved cytoplasmic C-terminal domain of occludin: Identification of the ZO-1 binding surface J. Mol. Biol. 2005 352 151 164 10.1016/j.jmb.2005.07.017 16081103
238. Yaffe Y. Shepshelovitch J. Nevo-Yassaf I. Yeheskel A. Shmerling H. Kwiatek J.M. Gaus K. Pasmanik-Chor M. Hirschberg K. The MARVEL transmembrane motif of occludin mediates oligomerization and targeting to the basolateral surface in epithelia J. Cell Sci. 2012 125 3545 3556 10.1242/jcs.100289 22492786
239. Siddiqui M.R. Mayanil C.S. Kim K.S. Tomita T. Angiopoietin-1 Regulates Brain Endothelial Permeability through PTPN-2 Mediated Tyrosine Dephosphorylation of Occludin PLoS ONE 2015 10 e0130857 10.1371/journal.pone.0130857 26090670
240. Titchenell P.M. Lin C.M. Keil J.M. Sundstrom J.M. Smith C.D. Antonetti D.A. Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction Biochem. J. 2012 446 455 467 10.1042/BJ20111961 22721706
241. Fischer S. Wiesnet M. Marti H.H. Renz D. Schaper W. Simultaneous activation of several second messengers in hypoxia-induced hyperpermeability of brain derived endothelial cells J. Cell. Physiol. 2004 198 359 369 10.1002/jcp.10417 14755541
242. Chen F. Hori T. Ohashi N. Baine A.M. Eckman C.B. Nguyen J.H. Occludin Is Regulated by Epidermal Growth Factor Receptor Activation in Brain Endothelial Cells and Brains of Mice with Acute Liver Failure Hepatology 2011 53 1294 1305 10.1002/hep.24161 21480332
243. Raikwar N.S. Vandewalle A. Thomas C.P. Nedd4-2 interacts with occludin to inhibit tight junction formation and enhance paracellular conductance in collecting duct epithelia Am. J. Physiol. Renal Physiol. 2010 299 F436 F444 10.1152/ajprenal.00674.2009 20504882
244. Traweger A. Fang D. Liu Y.C. Stelzhammer W. Krizbai I.A. Fresser F. Bauer H.C. Bauer H. The tight junction-specific protein occludin is a functional target of the E3 ubiquitin-protein ligase itch J. Biol. Chem. 2002 277 10201 10208 10.1074/jbc.M111384200 11782481
245. Zhang G.S. Tian Y. Huang J.Y. Tao R.R. Liao M.H. Lu Y.M. Ye W.F. Wang R. Fukunaga K. Lou Y.J. The g-Secretase Blocker DAPT Reduces the Permeability of the Blood-Brain Barrier by Decreasing the Ubiquitination and Degradation of Occludin During Permanent Brain Ischemia CNS Neurosci. Ther. 2013 19 53 60 10.1111/cns.12032 23171401
246. Leclair H.M. Andre-Gregoire G. Treps L. Azzi S. Bidere N. Gavard J. The E3 ubiquitin ligase MARCH3 controls the endothelial barrier FEBS Lett. 2016 590 3660 3668 10.1002/1873-3468.12417 27616439
247. Kebir H. Kreymborg K. Ifergan I. Dodelet-Devillers A. Cayrol R. Bernard M. Giuliani F. Arbour N. Becher B. Prat A. Human T(H)17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation Nat. Med. 2007 13 1173 1175 10.1038/nm1651 17828272
248. Lohmann C. Krischke M. Wegener J. Galla H.J. Tyrosine phosphatase inhibition induces loss of blood-brain barrier integrity by matrix metalloproteinase-dependent and -independent pathways Brain Res. 2004 995 184 196 10.1016/j.brainres.2003.10.002 14672808
249. Liu J. Jin X.C. Liu K.J. Liu W.L. Matrix Metalloproteinase-2-Mediated Occludin Degradation and Caveolin-1-Mediated Claudin-5 Redistribution Contribute to Blood-Brain Barrier Damage in Early Ischemic Stroke Stage J. Neurosci. 2012 32 3044 3057 10.1523/JNEUROSCI.6409-11.2012 22378877
250. Miyoshi Y. Tanabe S. Suzuki T. Cellular zinc is required for intestinal epithelial barrier maintenance via the regulation of claudin-3 and occludin expression Am. J. Physiol. Gastroint. Liver Physiol. 2016 311 G105 G116 10.1152/ajpgi.00405.2015 27151944
251. Li R.R. Qi Y.N. Jiang M. Zhang T.H. Wang H.W. Wang L.G. Han M.Y. Primary tumor-secreted VEGF induces vascular hyperpermeability in premetastatic lung via the occludin phosphorylation/ubiquitination pathway Mol. Carcinog. 2019 58 2316 2326 10.1002/mc.23120 31553086
252. Wang L.F. Li X. Gao Y.B. Wang S.M. Zhao L. Dong J. Yao B.W. Xu X.P. Chang G.M. Zhou H.M. Activation of VEGF/Flk-1-ERK Pathway Induced Blood-Brain Barrier Injury after Microwave Exposure Mol. Neurobiol. 2015 52 478 491 10.1007/s12035-014-8848-9 25195697
253. Muthusamy A. Lin C.M. Shanmugam S. Lindner H.M. Abcouwer S.F. Antonetti D.A. Ischemia-reperfusion injury induces occludin phosphorylation/ubiquitination and retinal vascular permeability in a VEGFR-2-dependent manner J. Cereb. Blood Flow Metab. 2014 34 522 531 10.1038/jcbfm.2013.230 24398936
254. Bauer A.T. Burgers H.F. Rabie T. Marti H.H. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement J. Cereb. Blood Flow Metab. 2010 30 837 848 10.1038/jcbfm.2009.248 19997118
255. Su P. Zhao F. Cao Z.P. Zhang J.B. Aschner M. Luo W.J. Mir-203-mediated tricellulin mediates lead-induced in vitro loss of blood-cerebrospinal fluid barrier (BCB) function Toxicol. Vitr. 2015 29 1185 1194 10.1016/j.tiv.2015.05.002 25975750
256. Ikenouchi J. Furuse M. Furuse K. Sasaki H. Tsukita S. Tsukita S. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells J. Cell Biol. 2005 171 939 945 10.1083/jcb.200510043 16365161
257. Ikenouchi J. Sasaki H. Tsukita S. Furuse M. Tsukita S. Loss of Occludin Affects Tricellular Localization of Tricellulin Mol. Biol. Cell 2008 19 4687 4693 10.1091/mbc.e08-05-0530 18768749
258. Kamitani T. Sakaguchi H. Tamura A. Miyashita T. Yamazaki Y. Tokumasu R. Inamoto R. Matsubara A. Mori N. Hisa Y. Deletion of Tricellulin Causes Progressive Hearing Loss Associated with Degeneration of Cochlear Hair Cells Sci. Rep. 2015 5 12 10.1038/srep18402 26677943
259. Ayala-Torres C. Krug S.M. Schulzke J.D. Rosenthal R. Fromm M. Tricellulin Effect on Paracellular Water Transport Int. J. Mol. Sci. 2019 20 15 10.3390/ijms20225700 31739405
260. Cording J. Arslan B. Staat C. Dithmer S. Krug S.M. Kruger A. Berndt P. Gunther R. Winkler L. Blasig I.E. Trictide, a tricellulin-derived peptide to overcome cellular barriers Ann. N. Y. Acad. Sci. 2017 1405 89 101 10.1111/nyas.13392 28633193
261. Schuetz A. Radusheva V. Krug S.M. Heinemann U. Crystal structure of the tricellulin C-terminal coiled-coil domain reveals a unique mode of dimerization Ann. N. Y. Acad. Sci. 2017 1405 147 159 10.1111/nyas.13408 28661558
262. Oda Y. Otani T. Ikenouchi J. Furuse M. Tricellulin regulates junctional tension of epithelial cells at tricellular contacts through Cdc42 J. Cell Sci. 2014 127 4201 4212 25097232
263. Sumitomo T. Nakata M. Higashino M. Yamaguchi M. Kawabata S. Group A Streptococcus exploits human plasminogen for bacterial translocation across epithelial barrier via tricellular tight junctions Sci. Rep. 2016 6 13 10.1038/srep20069 28442757
264. Jennek S. Mittag S. Reiche J. Westphal J.K. Seelk S. Dorfel M.J. Pfirrmann T. Friedrich K. Schutz A. Heinemann U. Tricellulin is a target of the ubiquitin ligase Itch Ann. N. Y. Acad. Sci. 2017 1397 157 168 10.1111/nyas.13349 28436082
265. Takasawa A. Murata M. Takasawa K. Ono Y. Osanai M. Tanaka S. Nojima M. Kono T. Hirata K. Kojima T. Nuclear localization of tricellulin promotes the oncogenic property of pancreatic cancer Sci. Rep. 2016 6 12 10.1038/srep33582 28442744
266. Morampudi V. Graef F.A. Stahl M. Dalwadi U. Conlin V.S. Huang T. Vallance B.A. Yu H.B. Jacobson K. Tricellular Tight Junction Protein Tricellulin Is Targeted by the Enteropathogenic Escherichia coli Effector EspG1, Leading to Epithelial Barrier Disruption Infect. Immun. 2017 85 20 10.1128/IAI.00700-16 27795363
267. Krug S.M. Bojarski C. Fromm A. Lee I.M. Dames P. Richter J.F. Turner J.R. Fromm M. Schulzke J.D. Tricellulin is regulated via interleukin-13-receptor alpha 2, affects macromolecule uptake, and is decreased in ulcerative colitis Mucosal Immunol. 2018 11 345 356 10.1038/mi.2017.52 28612843
268. Markov A.G. Vishnevskaya O.N. Okorokova L.S. Fedorova A.A. Kruglova N.M. Rybalchenko O.V. Aschenbach J.R. Amasheh S. Cholera toxin perturbs the paracellular barrier in the small intestinal epithelium of rats by affecting claudin-2 and tricellulin Pflugers Arch. 2019 471 1183 1189 10.1007/s00424-019-02294-z 31222489
269. Eum S.Y. Jaraki D. Bertrand L. Andras I.E. Toborek M. Disruption of epithelial barrier by quorum-sensing N-3-(oxododecanoyl)-homoserine lactone is mediated by matrix metalloproteinases Am. J. Physiol. Gastroint. Liver Physiol. 2014 306 G992 G1001 10.1152/ajpgi.00016.2014 24742991
270. Janke S. Mittag S. Reiche J. Huber O. Apoptotic Fragmentation of Tricellulin Int. J. Mol. Sci. 2019 20 15 10.3390/ijms20194882 31581480
271. Fiorentino M. Sapone A. Senger S. Camhi S.S. Kadzielski S.M. Buie T.M. Kelly D.L. Cascella N. Fasano A. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders Mol. Autism 2016 7 49 10.1186/s13229-016-0110-z 27957319
272. Severson E.A. Jiang L. Ivanov A.I. Mandell K.J. Nusrat A. Parkos C.A. Cis-dimerization mediates function of junctional adhesion molecule A Mol. Biol. Cell 2008 19 1862 1872 10.1091/mbc.e07-09-0869 18272784
273. Itoh M. Sasaki H. Furuse M. Ozaki H. Kita T. Tsukita S. Junctional adhesion molecule (JAM) binds to PAR-3: A possible mechanism for the recruitment of PAR-3 to tight junctions J. Cell Biol. 2001 154 491 497 10.1083/jcb.200103047 11489913
274. Bazzoni G. Martinez-Estrada O.M. Mueller F. Nelboeck P. Schmid G. Bartfai T. Dejana E. Brockhaus M. Homophilic interaction of junctional adhesion molecule J. Biol. Chem. 2000 275 30970 30976 10.1074/jbc.M003946200 10913139
275. Lamagna C. Meda P. Mandicourt G. Brown J. Gilbert R.J.C. Jones E.Y. Kiefer F. Ruga P. Imhof B.A. Aurrand-Lions M. Dual interaction of JAM-C with JAM-B and alpha(M)beta(2) integrin: Function in junctional complexes and leukocyte adhesion Mol. Biol. Cell 2005 16 4992 5003 10.1091/mbc.e05-04-0310 16093349
276. Yeung D. Manias J.L. Stewart D.J. Nag S. Decreased junctional adhesion molecule-A expression during blood-brain barrier breakdown Acta Neuropathol. 2008 115 635 642 10.1007/s00401-008-0364-4 18357461
277. Aurrand-Lions M. Johnson-Leger C. Wong C. Du Pasquier L. Imhof B.A. Heterogeneity of endothelial junctions is reflected by differential expression and specific subcellular localization of the three JAM family members Blood 2001 98 3699 3707 10.1182/blood.V98.13.3699 11739175
278. Jia W. Martin T.A. Zhang G.B. Jiang W.G. Junctional Adhesion Molecules in Cerebral Endothelial Tight Junction and Brain Metastasis Anticancer Res. 2013 33 2353 2359 23749882
279. Kummer D. Ebnet K. Junctional Adhesion Molecules (JAMs): The JAM-Integrin Connection Cells 2018 7 12 10.3390/cells7040025 29419779
280. Naik M.U. Naik U.P. Junctional adhesion molecule-A-induced endothelial cell migration on vitronectin is integrin alpha(v)beta(3) specific J. Cell Sci. 2006 119 490 499 10.1242/jcs.02771 16418218
281. Ostermann G. Weber K.S.C. Zernecke A. Schroder A. Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes Nat. Immunol. 2002 3 151 158 10.1038/ni755 11812992
282. Santoso S. Sachs U.J.H. Kroll H. Linder M. Ruf A. Preissner K.T. Chavakis T. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1 J. Exp. Med. 2002 196 679 691 10.1084/jem.20020267 12208882
283. Tornavaca O. Chia M. Dufton N. Almagro L.O. Conway D.E. Randi A.M. Schwartz M.A. Matter K. Balda M.S. ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation J. Cell Biol. 2015 208 821 838 10.1083/jcb.201404140 25753039
284. Bazzoni G. The JAM family of junctional adhesion molecules Curr. Opin. Cell Biol. 2003 15 525 530 10.1016/S0955-0674(03)00104-2 14519386
285. Ebnet K. Junctional adhesion molecules (JAMs): Cell adhesion receptors with pleiotropic functions in cell physiology and development Physiol. Rev. 2017 97 1529 1554 10.1152/physrev.00004.2017 28931565
286. Ishida T. Kundu R.K. Yang E. Hirata K. Ho Y.D. Quertermous T. Targeted disruption of endothelial cell-selective adhesion molecule inhibits angiogenic processes in vitro and in vivo J. Biol. Chem. 2003 278 34598 34604 10.1074/jbc.M304890200 12819200
287. Wegmann F. Petri B. Khandoga A.G. Moser C. Khandoga A. Volkery S. Li H. Nasdala I. Brandau O. Fassler R. ESAM supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular permeability J. Exp. Med. 2006 203 1671 1677 10.1084/jem.20060565 16818677
288. Duong C.N. Nottebaum A.F. Butz S. Volkery S. Zeuschner D. Stehling M. Vestweber D. Interference with ESAM (Endothelial Cell-Selective Adhesion Molecule) Plus Vascular Endothelial-Cadherin Causes Immediate Lethality and Lung-Specific Blood Coagulation Arter. Thromb. Vasc. Biol. 2020 40 378 393 10.1161/ATVBAHA.119.313545 31826650
289. Stevenson B.R. Siliciano J.D. Mooseker M.S. Goodenough D.A. Identification of ZO-1—A high-molecular-weight polypeptide associated with the tight junction (Zonula occludens) in a variety of epithelia J. Cell Biol. 1986 103 755 766 10.1083/jcb.103.3.755 3528172
290. Anderson J.M. Stevenson B.R. Jesaitis L.A. Goodenough D.A. Mooseker M.S. Characterization of ZO-1, a Protein-Component of the Tight Junction from Mouse Liver and Madin-Darby Canine Kidney Cells J. Cell Biol. 1988 106 1141 1149 10.1083/jcb.106.4.1141 2452168
291. Jesaitis L.A. Goodenough D.A. Molecular characterization and tissue distribution of ZO-2, a tight junction protein homologous to ZO-1 and the drosophila disks-large tumor-suppressor protein J. Cell Biol. 1994 124 949 961 10.1083/jcb.124.6.949 8132716
292. Haskins J. Gu L.J. Wittchen E.S. Hibbard J. Stevenson B.R. ZO-3, a novel member of the MAGUK protein family found at the tight junction, interacts with ZO-1 and occludin J. Cell Biol. 1998 141 199 208 10.1083/jcb.141.1.199 9531559
293. Ikenouchi J. Umeda K. Tsukita S. Furuse M. Tsukita S. Requirement of ZO-1 for the formation of belt-like adherens junctions during epithelial cell polarization J. Cell Biol. 2007 176 779 786 10.1083/jcb.200612080 17353356
294. Giepmans B.N.G. Moolenaar W.H. The gap junction protein connexin43 interacts with the second PDZ domain of the zona occludens-1 protein Curr. Biol. 1998 8 931 934 10.1016/S0960-9822(07)00375-2 9707407
295. Fanning A.S. Anderson J.M. Zonula Occludens-1 and-2 Are Cytosolic Scaffolds That Regulate the Assembly of Cellular Junctions Molecular Structure and Function of the Tight Junction: From Basic Mechanisms to Clinical Manifestations Fromm M. Schulzke J.D. Wiley Online Library Hoboken, NJ, USA 2009 Volume 1165 113 120
296. Fanning A.S. Lye M.F. Anderson J.M. Lavie A. Domain swapping within PDZ2 is responsible for dimerization of ZO proteins J. Biol. Chem. 2007 282 37710 37716 10.1074/jbc.M707255200 17928286
297. Balda M.S. Matter K. The tight junction protein ZO-1 and an interacting transcription factor regulate ErbB-2 expression EMBO J. 2000 19 2024 2033 10.1093/emboj/19.9.2024 10790369
298. Bal M.S. Castro V. Piontek J. Rueckert C. Walter J.K. Shymanets A. Kurig B. Haase H. Nurnberg B. Blasig I.E. The hinge region of the scaffolding protein of cell contacts, zonula occludens protein 1, regulates interacting with various signaling proteins J. Cell. Biochem. 2012 113 934 945 10.1002/jcb.23422 22371973
299. Ye X. Wang Y. Cahill H. Yu M. Badea T.C. Smallwood P.M. Peachey N.S. Nathans J. Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization Cell 2009 139 285 298 10.1016/j.cell.2009.07.047 19837032
300. Fanning A.S. Ma T.Y. Anderson J.M. Isolation and functional characterization of the actin-binding region in the tight junction protein ZO-1 Faseb J. 2002 16 1 13 10.1096/fj.02-0121fje 11772930
301. Gottardi C.J. Arpin M. Fanning A.S. Louvard D. The junction-associated protein, zonula occludens-1, localizes to the nucleus before the maturation and during the remodeling of cell-cell contacts Proc. Natl. Acad. Sci. USA 1996 93 10779 10784 10.1073/pnas.93.20.10779 8855257
302. Traweger A. Fuchs R. Krizbai I.A. Weiger T.M. Bauer H.C. Bauer H. The tight junction protein ZO-2 localizes to the nucleus and interacts with the heterogeneous nuclear ribonucleoprotein scaffold attachment factor-B J. Biol. Chem. 2003 278 2692 2700 10.1074/jbc.M206821200 12403786
303. Umeda K. Ikenouchi J. Katahira-Tayama S. Furuse K. Sasaki H. Nakayama M. Matsui T. Tsukita S. Furuse M. Tsukita S. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation Cell 2006 126 741 754 10.1016/j.cell.2006.06.043 16923393
304. Fanning A.S. Van Itallie C.M. Anderson J.M. Zonula occludens-1 and-2 regulate apical cell structure and the zonula adherens cytoskeleton in polarized epithelia Mol. Biol. Cell 2012 23 577 590 10.1091/mbc.e11-09-0791 22190737
305. Huxham J. Tabaries S. Siegel P.M. Afadin (AF6) in cancer progression: A multidomain scaffold protein with complex and contradictory roles Bioessays 2020 17 e2000221 10.1002/bies.202000221 33165933
306. Vasileva E. Sluysmans S. Bochaton-Piallat M.L. Citi S. Cell-specific diversity in the expression and organization of cytoplasmic plaque proteins of apical junctions Ann. N. Y. Acad. Sci. 2017 1405 160 176 10.1111/nyas.13391 28617990
307. Zhai X. Li Y.L. Liang P. Li L.S. Zhou Y.D. Zhang W.D. Wang D.F. Wei G.H. PI3K/AKT/Afadin signaling pathway contributes to pathological vascularization in glioblastomas Oncol. Lett. 2018 15 1893 1899 10.3892/ol.2017.7461 29434887
308. Coureuil M. Mikaty G. Miller F. Lecuyer H. Bernard C. Bourdoulous S. Dumenil G. Mege R.M. Weksler B.B. Romero I.A. Meningococcal Type IV Pili Recruit the Polarity Complex to Cross the Brain Endothelium Science 2009 325 83 87 10.1126/science.1173196 19520910
309. Worzfeld T. Schwaninger M. Apicobasal polarity of brain endothelial cells J. Cereb. Blood Flow Metab. 2016 36 340 362 10.1177/0271678X15608644 26661193
310. Cho C. Wang Y. Smallwood P.M. Williams J. Nathans J. Dlg1 activates beta-catenin signaling to regulate retinal angiogenesis and the blood-retina and blood-brain barriers eLife 2019 8 e45542 10.7554/eLife.45542 31066677
311. Sewduth R.N. Kovacic H. Jaspard-Vinassa B. Jecko V. Wavasseur T. Fritsch N. Pernot M. Jeaningros S. Roux E. Dufourcq P. PDZRN3 destabilizes endothelial cell-cell junctions through a PKC zeta-containing polarity complex to increase vascular permeability Sci. Signal. 2017 10 eaag3209 10.1126/scisignal.aag3209 28143902
312. Chrifi I. Hermkens D. Brandt M.M. van Dijk C.G.M. Burgisser P.E. Haasdijk R. Pei J.Y. van de Kamp E.H.M. Zhu C.B. Blonden L. Cgnl1, an endothelial junction complex protein, regulates GTPase mediated angiogenesis Cardiovasc. Res. 2017 113 1776 1788 10.1093/cvr/cvx175 29016873
313. Huber J.D. Witt K.A. Hom S. Egleton R.D. Mark K.S. Davis T.P. Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression Am. J. Physiol. Heart Circ. Physiol. 2001 280 H1241 H1248 10.1152/ajpheart.2001.280.3.H1241 11179069
314. Greene C. Kealy J. Humphries M.M. Gong Y. Hou J. Hudson N. Cassidy L.M. Martiniano R. Shashi V. Hooper S.R. Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia Mol. Psychiatr. 2018 23 2156 2166 10.1038/mp.2017.156 28993710
315. Montagne A. Zhao Z. Zlokovic B.V. Alzheimer’s disease: A matter of blood-brain barrier dysfunction? J. Exp. Med. 2017 214 3151 3169 10.1084/jem.20171406 29061693
316. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders Nat. Rev. Neurosci. 2011 12 723 738 10.1038/nrn3114 22048062
317. Rosenberg G.A. Neurological diseases in relation to the blood-brain barrier J. Cereb. Blood Flow Metab. 2012 32 1139 1151 10.1038/jcbfm.2011.197 22252235
318. Al-Ahmad A.J. Human-Induced Pluripotent Stem Cell-Based Model of the Blood-Brain at 10 Years: A Retrospective on Past and Current Disease Models Handb. Exp. Pharmacol. 2023 281 141 156 36943490
319. Biron K.E. Dickstein D.L. Gopaul R. Jefferies W.A. Amyloid Triggers Extensive Cerebral Angiogenesis Causing Blood Brain Barrier Permeability and Hypervascularity in Alzheimer’s Disease PLoS ONE 2011 6 e23789 10.1371/journal.pone.0023789 21909359
320. Hartz A.M.S. Bauer B. Soldner E.L.B. Wolf A. Boy S. Backhaus R. Mihaljevic I. Bogdahn U. Klunemann H.H. Schuierer G. Amyloid-beta Contributes to Blood-Brain Barrier Leakage in Transgenic Human Amyloid Precursor Protein Mice and in Humans With Cerebral Amyloid Angiopathy Stroke 2012 43 514 523 10.1161/STROKEAHA.111.627562 22116809
321. Oikari L.E. Pandit R. Stewart R. Cuni-Lopez C. Quek H. Sutharsan R. Rantanen L.M. Oksanen M. Lehtonen S. de Boer C.M. Altered Brain Endothelial Cell Phenotype from a Familial Alzheimer Mutation and Its Potential Implications for Amyloid Clearance and Drug Delivery Stem Cell Rep. 2020 14 924 939 10.1016/j.stemcr.2020.03.011 32275861
322. Alvarez J.I. Cayrol R. Prat A. Disruption of central nervous system barriers in multiple sclerosis Biochim. Biophys. Acta Mol. Basis Dis. 2011 1812 252 264 10.1016/j.bbadis.2010.06.017 20619340
323. Henkel J.S. Beers D.R. Wen S. Bowser R. Appel S.H. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS Neurology 2009 72 1614 1616 10.1212/WNL.0b013e3181a41228 19414730
324. Zhong Z. Deane R. Ali Z. Parisi M. Shapovalov Y. O’Banion M.K. Stojanovic K. Sagare A. Boillee S. Cleveland D.W. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration Nat. Neurosci. 2008 11 420 422 10.1038/nn2073 18344992
325. Gray M.T. Woulfe J.M. Striatal blood-brain barrier permeability in Parkinson’s disease J. Cereb. Blood Flow Metab. 2015 35 747 750 10.1038/jcbfm.2015.32 25757748
326. Wu X.L. Wang P. Liu Y.H. Xue Y.X. Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson’s disease J. Mol. Neurosci. 2014 53 1 9 10.1007/s12031-013-0175-5 24254220
327. Drouin-Ouellet J. Sawiak S.J. Cisbani G. Lagace M. Kuan W.L. Saint-Pierre M. Dury R.J. Alata W. St-Amour I. Mason S.L. Cerebrovascular and blood-brain barrier impairments in Huntington’s disease: Potential implications for its pathophysiology Ann. Neurol. 2015 78 160 177 10.1002/ana.24406 25866151
328. Linville R.M. Nerenberg R.F. Grifno G. Arevalo D. Guo Z. Searson P.C. Brain microvascular endothelial cell dysfunction in an isogenic juvenile iPSC model of Huntington’s disease Fluids Barriers CNS 2022 19 54 10.1186/s12987-022-00347-7 35773691
329. Greene C. Hanley N. Reschke C.R. Reddy A. Mae M.A. Connolly R. Behan C. O’Keeffe E. Bolger I. Hudson N. Microvascular stabilization via blood-brain barrier regulation prevents seizure activity Nat. Commun. 2022 13 2003 10.1038/s41467-022-29657-y 35422069
330. Kealy J. Greene C. Campbell M. Blood-brain barrier regulation in psychiatric disorders Neurosci. Lett. 2020 726 14 10.1016/j.neulet.2018.06.033
331. On N.H. Mitchell R. Savant S.D. Bachmeier C.J. Hatch G.M. Miller D.W. Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model J. Neuro Oncol. 2013 111 133 143 10.1007/s11060-012-1006-1 23184143
332. Wen L.J. Tan Y.A. Dai S.H. Zhu Y. Meng T.T. Yang X.Q. Liu Y.P. Liu X. Yuan H. Hu F.Q. VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy Drug Deliv. 2017 24 1843 1855 10.1080/10717544.2017.1386731 29182025
333. Higashida T. Kreipke C.W. Rafols J.A. Peng C.Y. Schafer S. Schafer P. Ding J.Y. Dornbos D. Li X.H. Guthikonda M. The role of hypoxia-inducible factor-la, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury Laboratory investigation J. Neurosurg. 2011 114 92 101 10.3171/2010.6.JNS10207 20617879
334. Jungner M. Siemund R. Venturoli D. Reinstrup P. Schalen W. Bentzer P. Blood-brain barrier permeability following traumatic brain injury Minerva Anestesiol. 2016 82 525 533 10.1186/cc10919 26613239
335. Campbell M. Hanrahan F. Gobbo O.L. Kelly M.E. Kiang A.S. Humphries M.M. Nguyen A.T.H. Ozaki E. Keaney J. Blau C.W. Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury Nat. Commun. 2012 3 849 10.1038/ncomms1852 22617289
336. Huang J. Cao Y. Chang S. An inhibitor of claudin-5 interactions, M01, alleviates neuroinflammation and vasogenic edema after blood-spinal cord barrier dysfunction NeuroReport 2023 34 512 520 10.1097/WNR.0000000000001919 37270843
337. Merali Z. Huang K. Mikulis D. Silver F. Kassner A. Evolution of blood-brain-barrier permeability after acute ischemic stroke PLoS ONE 2017 12 e0171558 10.1371/journal.pone.0171558 28207745
338. Jiao H.X. Wang Z.H. Liu Y.H. Wang P. Xue Y.X. Specific Role of Tight Junction Proteins Claudin-5, Occludin, and ZO-1 of the Blood-Brain Barrier in a Focal Cerebral Ischemic Insult J. Mol. Neurosci. 2011 44 130 139 10.1007/s12031-011-9496-4 21318404
339. Ku J.M. Taher M. Chin K.Y. Grace M. McIntyre P. Miller A.A. Characterisation of a mouse cerebral microvascular endothelial cell line (bEnd.3) after oxygen glucose deprivation and reoxygenation Clin. Exp. Pharmacol. Physiol. 2016 43 777 786 10.1111/1440-1681.12587 27128638
340. Venkat P. Chopp M. Chen J. Blood-Brain Barrier Disruption, Vascular Impairment, and Ischemia/Reperfusion Damage in Diabetic Stroke J. Am. Heart Assoc. 2017 6 e005819 10.1161/JAHA.117.005819 28572280
341. Yan Z. Wang C. Meng Z. Gan L. Guo R. Liu J. Bond Lau W. Xie D. Zhao J. Lopez B.L. C1q/TNF-Related Protein 3 Prevents Diabetic Retinopathy via AMPK-Dependent Stabilization of Blood-Retinal Barrier Tight Junctions Cells 2022 11 779 10.3390/cells11050779 35269401
342. Arba F. Leigh R. Inzitari D. Warach S.J. Luby M. Lees K.R. Collaboration S.V.I. Blood-brain barrier leakage increases with small vessel disease in acute ischemic stroke Neurology 2017 89 2143 2150 10.1212/WNL.0000000000004677 29070665
343. Al-Thani M. Goodwin-Trotman M. Bell S. Patel K. Fleming L.K. Vilain C. Abramowicz M. Allan S.M. Wang T. Cader M.Z. A novel human iPSC model of COL4A1/A2 small vessel disease unveils a key pathogenic role of matrix metalloproteinases Stem Cell Rep. 2023 18 2386 2399 10.1016/j.stemcr.2023.10.014 37977146
344. El-Khouly F.E. Haumann R. Breur M. Veldhuijzen van Zanten S.E.M. Kaspers G.J.L. Hendrikse N.H. Hulleman E. van Vuurden D.G. Bugiani M. The neurovascular unit in diffuse intrinsic pontine gliomas Free Neuropathol. 2021 2 2 17 37284626
345. Li C. Jiang Z. Lu W. Arrick D. McCarter K. Sun H. Effect of obesity on early blood-brain barrier disruption following transient focal cerebral ischemia Obes. Sci. Pract. 2016 2 58 68 10.1002/osp4.30
346. Argaw A.T. Asp L. Zhang J.Y. Navrazhina K. Pham T. Mariani J.N. Mahase S. Dutta D.J. Seto J. Kramer E.G. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease J. Clin. Investig. 2012 122 2454 2468 10.1172/JCI60842 22653056
347. Schellenberg A.E. Buist R. Del Bigio M.R. Toft-Hansen H. Khorooshi R. Owens T. Peeling J. Blood-brain barrier disruption in CCL2 transgenic mice during pertussis toxin-induced brain inflammation Fluids Barriers CNS 2012 9 10 10.1186/2045-8118-9-10 22546091
348. Xie H. Xue Y.X. Liu L.B. Liu Y.H. Endothelial-monocyte-activating polypeptide II increases blood-tumor barrier permeability by down-regulating the expression levels of tight junction associated proteins Brain Res. 2010 1319 13 20 10.1016/j.brainres.2010.01.023 20083091
349. Guo P. Liu L. Yang X. Li M. Zhao Q. Wu H. Irisin improves BBB dysfunction in SAP rats by inhibiting MMP-9 via the ERK/NF-kappaB signaling pathway Cell. Signal. 2022 93 110300 10.1016/j.cellsig.2022.110300 35259454
350. Leda A.R. Bertrand L. Andras I.E. El-Hage N. Nair M. Toborek M. Selective Disruption of the Blood-Brain Barrier by Zika Virus Front. Microbiol. 2019 10 2158 10.3389/fmicb.2019.02158 31620112
351. Bhardwaj U. Singh S.K. Zika Virus NS1 Suppresses VE-Cadherin and Claudin-5 via hsa-miR-101-3p in Human Brain Microvascular Endothelial Cells Mol. Neurobiol. 2021 58 6290 6303 10.1007/s12035-021-02548-x 34487317
352. Shrestha B. Paul D. Pachter J.S. Alterations in tight junction protein and IgG permeability accompany leukocyte extravasation across the choroid plexus during neuroinflammation J. Neuropathol. Exp. Neurol. 2014 73 1047 1061 10.1097/NEN.0000000000000127 25289890
353. Huggins M.A. Johnson H.L. Jin F. N’Songo A. Hanson L.M. LaFrance S.J. Butler N.S. Harty J.T. Johnson A.J. Perforin Expression by CD8 T Cells Is Sufficient To Cause Fatal Brain Edema during Experimental Cerebral Malaria Infect. Immun. 2017 85 e00985-16 10.1128/IAI.00985-16 28264905
354. Endres L.M. Jungblut M. Divyapicigil M. Sauer M. Stigloher C. Christodoulides M. Kim B.J. Schubert-Unkmeir A. Development of a multicellular in vitro model of the meningeal blood-CSF barrier to study Neisseria meningitidis infection Fluids Barriers CNS 2022 19 81 10.1186/s12987-022-00379-z 36289516
355. Greene C. Connolly R. Brennan D. Laffan A. O’Keeffe E. Zaporojan L. O’Callaghan J. Thomson B. Connolly E. Argue R. Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment Nat. Neurosci. 2024 27 421 432 10.1038/s41593-024-01576-9 38388736
356. Amruta N. Ismael S. Leist S.R. Gressett T.E. Srivastava A. Dinnon K.H. III Engler-Chiurazzi E.B. Maness N.J. Qin X. Kolls J.K. Mouse Adapted SARS-CoV-2 (MA10) Viral Infection Induces Neuroinflammation in Standard Laboratory Mice Viruses 2022 15 114 10.3390/v15010114 36680154
357. Mohammadi M.T. Dehghani G.A. Acute hypertension induces brain injury and blood-brain barrier disruption through reduction of claudins mRNA expression in rat Pathol. Res. Pract. 2014 210 985 990 10.1016/j.prp.2014.05.007 24996562
358. Rubio-Araiz A. Porcu F. Perez-Hernandez M. Garcia-Gutierrez M.S. Aracil-Fernandez M.A. Gutierrez-Lopez M.D. Guerri C. Manzanares J. O’Shea E. Colado M.I. Disruption of blood-brain barrier integrity in postmortem alcoholic brain: Preclinical evidence of TLR4 involvement from a binge-like drinking model Addict. Biol. 2017 22 1103 1116 10.1111/adb.12376 26949123
359. Costea L. Meszaros A. Bauer H. Bauer H.C. Traweger A. Wilhelm I. Farkas A.E. Krizbai I.A. The Blood-Brain Barrier and Its Intercellular Junctions in Age-Related Brain Disorders Int. J. Mol. Sci. 2019 20 28 10.3390/ijms20215472 31684130
360. Tachibana K. Hirayama R. Sato N. Hattori K. Kato T. Takeda H. Kondoh M. Association of Plasma Claudin-5 with Age and Alzheimer Disease Int. J. Mol. Sci. 2024 25 13 10.3390/ijms25031419 38338697
361. Ni C. Wang C. Zhang J. Qu L. Liu X. Lu Y. Yang W. Deng J. Lorenz D. Gao P. Interferon-gamma safeguards blood-brain barrier during experimental autoimmune encephalomyelitis Am. J. Pathol. 2014 184 3308 3320 10.1016/j.ajpath.2014.08.019 25307346
362. Nayak L. Lee E.Q. Wen P.Y. Epidemiology of Brain Metastases Curr. Oncol. Rep. 2012 14 48 54 10.1007/s11912-011-0203-y 22012633
363. Michinaga S. Koyama Y. Pathogenesis of Brain Edema and Investigation into Anti-Edema Drugs Int. J. Mol. Sci. 2015 16 9949 9975 10.3390/ijms16059949 25941935
364. Sandoval K.E. Witt K.A. Blood-brain barrier tight junction permeability and ischemic stroke Neurobiol. Dis. 2008 32 200 219 10.1016/j.nbd.2008.08.005 18790057
365. Tian Y. Milic J. Monasor L.S. Chakraborty R. Wang S. Yuan Y. Asare Y. Behrends C. Tahirovic S. Bernhagen J. The COP9 signalosome reduces neuroinflammation and attenuates ischemic neuronal stress in organotypic brain slice culture model Cell. Mol. Life Sci. 2023 80 262 10.1007/s00018-023-04911-8 37597109
366. Cheng Z. Wang L. Qu M. Liang H. Li W. Li Y. Deng L. Zhang Z. Yang G.Y. Mesenchymal stem cells attenuate blood-brain barrier leakage after cerebral ischemia in mice J. Neuroinflamm. 2018 15 135 10.1186/s12974-018-1153-1 29724240
367. Sheng Y. Duan X. Liu Y. Li F. Ma S. Shang X. Wang X. Liu Y. Xue R. Qin Z. Tie2-expressing monocytes/macrophages promote cerebral revascularization in peri-infarct lesions upon ischemic insult Signal Transduct. Target. Ther. 2021 6 295 10.1038/s41392-021-00637-w 34366430
368. Easton A.S. Fraser P.A. Variable restriction of albumin diffusion across inflamed cerebral microvessels of the anaesthetized rat J. Physiol. 1994 475 147 157 10.1113/jphysiol.1994.sp020056 8189387
369. Breitkreuz-Korff O. Tscheik C. Del Vecchio G. Dithmer S. Walther W. Orthmann A. Wolburg H. Haseloff R.F. Schroder L. Blasig I.E. M01 as a novel drug enhancer for specifically targeting the blood-brain barrier J. Control. Release 2021 338 137 148 10.1016/j.jconrel.2021.08.014 34384796
370. Campbell M. Humphries M.M. Kiang A.S. Nguyen A.T. Gobbo O.L. Tam L.C. Suzuki M. Hanrahan F. Ozaki E. Farrar G.J. Systemic low-molecular weight drug delivery to pre-selected neuronal regions EMBO Mol. Med. 2011 3 235 245 10.1002/emmm.201100126 21374818
371. Hashimoto Y. Shirakura K. Okada Y. Takeda H. Endo K. Tamura M. Watari A. Sadamura Y. Sawasaki T. Doi T. Claudin-5-Binders Enhance Permeation of Solutes across the Blood-Brain Barrier in a Mammalian Model J. Pharmacol. Exp. Ther. 2017 363 275 283 10.1124/jpet.117.243014 28819070
372. Johnson P.H. Quay S.C. Advances in nasal drug delivery through tight junction technology Expert Opin. Drug Deliv. 2005 2 281 298 10.1517/17425247.2.2.281 16296754
373. Herman R.E. Makienko E.G. Prieve M.G. Fuller M. Houston M.E. Johnson P.H. Phage display screening of epithelial cell monolayers treated with EGTA: Identification of peptide FDFWITP that modulates tight junction activity J. Biomol. Screen 2007 12 1092 1101 10.1177/1087057107310216 18040053
374. Chen S.C. Eiting K. Cui K.Y. Leonard A.K. Morris D. Li C.Y. Farber K. Sileno A.P. Houston M.E. Johnson P.H. Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery J. Pharm. Sci. 2006 95 1364 1371 10.1002/jps.20510 16625659
375. Zeniya S. Kuwahara H. Daizo K. Watari A. Kondoh M. Yoshida-Tanaka K. Kaburagi H. Asada K. Nagata T. Nagahama M. Angubindin-1 opens the blood-brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system J. Control. Release 2018 283 126 134 10.1016/j.jconrel.2018.05.010 29753959
